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ABSTRACT OF THE DISSERTATION
IR820 NANOCONJUGATES FOR THERANOSTIC APPLICATIONS
by
Alicia Fernandez-Fernandez
Florida International University, 2013
Miami, Florida
Professor Anthony J. McGoron, Major Professor
Near-infrared dyes can be used as theranostic agents in cancer management based on
their optical imaging and localized hyperthermia capabilities. However, their clinical
translatability is limited by issues such as photobleaching, short circulation times, and
non-specific biodistribution. We studied the applications of IR820 in optical imaging and
hyperthermia, and we prepared nanoconjugate formulations to overcome some of the
aforementioned limitations. Free IR820 can be used for optical imaging, with a strong
signal still present 24 hours after i.v. injection, an elimination plasma half-life in the
order of hours, and primary biodistribution to liver, lung, and kidneys. After 808-mn laser
exposure, IR820 can also raise in vitro temperatures to the 41-43°C range that can
selectively inhibit cancer cell growth. We conjugated IR820 with PEG-diamine via ionic
interactions to create nanoconjugates (IR820-PDNCs) with diameters of approximately
50-nm per SEM and a zeta potential of 2.0±0.9 mV. IR820-PDNCs enhanced cellular
internalization compared to IR820 for imaging in SKOV-3, MES-SA, and Dx5 cancer
cells.

The

nanoconjugates

also

significantly

enhanced

hyperthermia-mediated

cytotoxicity in MES-SA and Dx5 compared to the free dye (p<0.05). Covalent
conjugation of IR820 with PEG-diamine for further stabilization resulted in
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nanoconjugates (IRPDcov) that have potential for in vivo applications. Our IRPDcov
formulation retained the ability to fluoresce and to cause hyperthermia-mediated cellgrowth inhibition, with enhanced internalization and significantly enhanced cytotoxic
hyperthermia effects compared to free dye. Additionally, IRPDcov demonstrated
significantly longer (p<0.05) plasma half-lives, elimination half-lives, and area-underthe-curve values compared to IR820, indicating larger overall exposure to the theranostic
agent. The IRPDcov conjugate had different organ localization than free IR820, with
potential reduced accumulation in the kidneys and significantly lower (p<0.05)
accumulation in the lungs. Some potential advantages of IR820-PEG-diamine
nanoconjugates may include passive targeting of tumor tissue through the enhanced
permeability and retention effect, prolonged circulation times resulting in increased
windows for combined diagnosis and therapy, and further opportunities for
functionalization, targeting, and customization. The conjugation of PEG-diamine with a
NIR dye provides a multifunctional delivery vector whose localization can be monitored
with noninvasive techniques and that may also serve for guided hyperthermia cancer
treatments.
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CHAPTER 1: INTRODUCTION, LITERATURE REVIEW,
AND SPECIFIC AIMS

1.1. Background and Relevance
1.1.1. The field of theranostics

Advances in early cancer diagnosis and therapy have improved the survival statistics of
individuals with cancer in the last few decades. Based on data collected 2001-2007, the 5year relative survival rate in cancer patients is 67%, which is 18% higher than thirty years
ago (ACS, 2012). The use of multifunctional modalities which possess diagnostic and
therapeutic properties, referred to as theranostics, can further enhance cancer
management by enabling a combined approach to detection and treatment (Xie et al.,
2010). In many cases, early detection is the most important variable affecting the choice
of therapeutic intervention and regimen. The timeline for detection of a tumor will impact
the feasibility of surgical resection without the need for adjuvant treatment. In later stages
of cancer, a combination of management approaches will be needed, which typically
include surgery, radiation, and chemotherapy (Minev, 2011).

One of the main challenges in combining early diagnosis and therapy is that imaging and
therapeutic probes are typically different in terms of selectivity and biodistribution
(Kelkar et al., 2011). This complicates the process of monitoring responses to treatment,
which in turn creates difficulties in planning, timing, and assessing the success of
interventions. By combining both therapy and diagnostic capabilities into a single
platform, theranostic agents provide clinicians with a multipurpose tool that can be used
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to detect, image, treat, and monitor therapeutic response over time (Sumer et al., 2008).
As a result, clinicians can implement therapy at an earlier stage, as well as achieve
increased safety, sensitivity and efficacy in heterogeneously natured diseases such as
cancer (Melancon et al., 2012; Sumer et al., 2008). The ability to monitor disease
progression in a more effective manner can also reduce delays in implementing plan of
care changes when therapy regimes need to be adjusted.

From the patient’s point of view, quality of care may be enhanced as well. Theranostic
management strategies could minimize the need for repeated medical procedures that
may involve multiple office visits or hospital stays, increased risk of side effects,
increased risk of dosage or medical errors, delayed therapeutic interventions, discomfort,
and impact on their psychological well-being and quality of life.

1.1.2. Multifunctional agents used in theranostic applications: the advantages of
nanomaterials

Multifunctional approaches may be crucial to the development of customizable early
detection systems, tailored cancer therapies, real-time monitoring of treatment
progression, and clinically translatable advances in cancer diagnosis, intervention and
prognosis (Fernandez-Fernandez et al., 2011). Although the field of theranostics is still
in its infancy in terms of development, there has been an explosion of research in this
field in the past few years, in part related to parallel developments in nanotechnology.
Many nanomaterials have built-in imaging capabilities, and can be modified to become
multifunctional by combining them with a therapeutic agent via entrapment, conjugation,
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or adsorption; or by exploiting their inherent therapeutic properties such as heat
generation hyperthermia or singlet oxygen generation for photodynamic applications.
Additionally, nanoparticles can circumvent some delivery challenges, such as those posed
by multidrug resistance phenomena and in some cases by physiological barriers, such as
the blood-brain barrier (Zamboni et al., 2012).

The fact that both diagnosis and therapy require sufficient accumulation in target tissues
is another reason why nanoformulations provide a desirable platform for theranostic
purposes (Bharali et al., 2010; Xie et al., 2010). Due to their small size, nanoparticles are
less susceptible to reticuloendothelial system clearance than larger agents, and for sizes
around 100 nm with near neutral charge, they have better in vivo penetration into tissues
and cells (Brigger et al., 2002; Xu et al., 2006). The enhanced permeability and retention
effect (EPR) also provides nanosize vehicles with the inherent advantage of passive
targeting to tumor sites (Iyer et al., 2006; Maeda, 2010; Maeda et al., 2000). When tumor
tissues are compared to healthy tissues, research has found several anatomical and
physiological differences, including larger pore sizes and increased leakiness, shape
irregularities, and reduced lymphatic clearance (Kelkar et al., 2011). The end result is that
there is preferential accumulation of nanoformulations in tumors due to enhanced
delivery and reduced clearance from tumor tissues, which may translate into increased
treatment efficacy and reduced systemic toxicity (Maeda et al., 2009; Maeda et al., 2000),
although this approach is limited by its lack of true specificity. Another characteristic of
many tumors is active angiogenesis, which increases blood vessel availability in the
tumor area (Maeda, 2010). It is also possible to artificially enhance the EPR effect by
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increasing regional blood pressure, or through the use of nitric oxide donors in the case of
hypoxic tumors. Both of these approaches have been demonstrated to be successful in
humans in increasing drug accumulation at target sites via nanocarriers (Maeda, 2010).
Still, more specific approaches to deliver these formulations would be desirable, given
that cancer is by definition a heterogeneous problem.

To overcome the limitations of passive targeting, nanoformulations can be actively
targeted by decoration or conjugation with moieties such as small ligands, antibodies, or
biomarkers that can direct them towards specific molecular targets, resulting in increased
selectivity and specificity of cellular uptake (Fernandez-Fernandez et al., 2011).
Additionally, nanoformulations can be coated with different substances to provide
specific desirable properties. An excellent example is coating of nanoparticles with
polyethylene glycol (PEG), either via adsorption or covalent conjugation, to obtain
stealth formulations and reduce biological elimination. PEG is a hydrophilic polymer that
reduces non-specific interactions with proteins, which would lead to subsequent
phagocytosis of the nanosystems by circulating immune system agents such as
macrophages. The mechanism by which PEG exerts this function is primarily through
steric repulsion as well as surface charge shielding effects, so that PEGylation results in
long-circulating formulations (Bazile et al., 1995; Gref et al., 2000; Li et al., 2001;
Moghimi et al., 2001; Peracchia et al., 1999; Scott et al., 1998). PEGylation also
minimizes van der Waals attractions between particles, resulting in reduced aggregation
behaviors that would lead to additional reticuloendothelial system recognition and
elimination (Jokerst et al., 2011); and it also reduces metabolic degradation by enzymes

4

(Veronese et al., 2005). Covalent attachment of PEG chains does not affect chain
properties in solution, so that formulations where PEG has been covalently attached will
maintain their functionality (Alexis et al., 2008; Hrkach et al., 1997). PEGylation is
considered a safe procedure for molecules destined for human use, with a therapeutic
index of at least 600-fold between PEGylated products and PEG exposure levels that are
toxic to humans (Webster et al., 2007).

1.1.3. Multifunctional agents used in theranostic applications: image-guided therapy

The imaging capability of a theranostic agent is often crucial for detection and
monitoring purposes (Caldorera-Moore et al., 2011). Molecular imaging agents can be
used as a diagnostic tool to visualize tissues and also to measure cellular processes related
to disease. Nuclear imaging techniques such as PET and SPECT can provide valuable
functional information, but have some disadvantages such as radiation exposure and
complexity of the equipment (Janib et al., 2010). Optical imaging methods have high
sensitivity, are inexpensive, and can be incorporated into fiber optic systems allowing for
minimally invasive approaches; but they are limited by absorption and scattering, which
result in low penetration (Alfano et al., 1997). This limitation can be alleviated by the use
of near-infrared (NIR) imaging agents. At wavelengths between 700 and 900 nm, in vivo
absorption and scattering processes are reduced due to decreased interaction with
biological cromophores compared to shorter wavelengths of light (Simpson et al., 1998).
This property results in improved tissue penetration for in vivo NIR optical imaging
compared to optical imaging at shorter wavelengths (Bloch et al., 2005).
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Nanoparticles have been used for applications involving MRI, CT, nuclear, and optical
imaging (Kang, 2010; Lee et al., 2008), and multifunctional nanoparticle designs allow
for simultaneous in vivo delivery of imaging and therapeutic agents (Kim et al., 2010). In
some cases, the intrinsic properties of the nanoparticle allow it to be used as an imaging
agent and/or an agent for hyperthermia, radiation, or photodynamic therapy applications.
This provides opportunities for image-guided therapy and truly integrated theranostic
systems (Fernandez-Fernandez et al., 2011).

For example, iron-oxide nanoparticles can be used as MRI probes and as hyperthermia
agents, and can also be loaded with chemotherapy agents to serve as drug delivery
carriers (Wust et al., 2006; Yu et al., 2008). Gold nanoformulations such as nanospheres,
nanorods, nanoshells, and nanocages have been applied to optical imaging, CT imaging,
photothermal therapy, drug delivery, and combined imaging and therapy (Huang et al.,
2008; Huff et al., 2007; Oyelere et al., 2007; von Maltzahn et al., 2009). Silica-based
formulations have also been applied for multifunctional purposes in combination with
other agents. Benachour et al have recently reported the preparation of multifunctional
silica-based nanoparticles with encapsulated chlorin for photodynamic therapy, and
decorated with gadolinium to serve as an MRI contrast agent as well as with peptides for
active targeting (Benachour et al., 2012). Some NIR dyes such as cyanine dyes,
rhodamine-based formulations, phtalocyanine and napthalocyanine can also be used as
photothermal and imaging agents (Bandichhor et al., 2006; Hilderbrand et al., 2005;
Patonay et al., 2004). Cyanine dyes have large molar extinction coefficients, mid-range
fluorescence quantum yields, and a wide choice of tunable wavelengths (Hilderbrand et
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al., 2005; Patonay et al., 2004; Zaheer et al., 2001), which makes them attractive for in
vivo applications.

1.1.4. The cyanine dyes indocyanine green and IR820 and their applications in imaging
and hyperthermia

An example of a cyanine NIR dye with multifunctional applications is indocyanine green
(ICG), which has been utilized for many years in clinical measurement of cardiac output,
evaluation of liver and kidney function, photodynamic therapy, photothermal therapy and
imaging (Dorshow et al., 1998; Johansen, 1990), and has low toxicity. Upon excitation by
light, ICG can release energy as emitted fluorescence photons, as well as through nonradiative internal conversion and heat emission. Although the heat generation efficiency
of ICG is smaller than that of gold nanoparticles (Hirsch et al., 2003; O'Neal et al., 2004),
ICG is able to rapidly elevate temperature upon laser excitation to therapeutic thermal
ranges that can selectively kill cancer cells (Abels et al., 2000; Chen et al., 1996; Tang et
al., 2009). Hyperthermia has been widely utilized as an adjuvant treatment for cancer
(Luk et al., 1980; van der Zee, 2002), and is less prone to toxic side eﬀects than other
therapeutic approaches such as chemotherapy (Kelkar et al., 2011). Cell culture, animal
and human studies have also shown that hyperthermia has a synergistic effect with other
cancer therapeutic modalities (Fotopoulou et al., 2010; Tang et al., 2009; West et al.,
1980; Wust et al., 2002).

The main challenge of using ICG in vivo is its poor stability in aqueous solution and fast
degradation rates, as well as its very short plasma half-life in the order of 3 to 5 minutes
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(Desmettre et al., 2000; Haller et al., 1993; Saxena et al., 2003). This limits the in vivo
therapeutic window for hyperthermia, imaging, or a dual combination using ICG,
especially in the case of the combinational approach, where timing of the diagnostic and
the therapeutic components may be an issue. In order for a multifunctional approach to be
effective and clinically translatable, the combined diagnostic and therapeutic windows
have to be large enough to make both processes practically feasible. If the window of
opportunity is very short, it becomes very difficult to use the diagnostic information to
guide therapy, or to follow the effects of therapy during a subsequent monitoring period.
Since the main mechanism of fluorescence degradation in ICG is the formation of
weakly-fluorescing ICG aggregates via intermolecular interactions (Zhou et al., 1994),
some groups have attempted to increase the stability of ICG using stabilizer additives
such as the Poly-(α,β)-DL-aspartic acid sodium salt PASP (Maarek et al., 2001;
Rajagopalan et al., 2000). However, the additive can complicate the incorporation of the
dye into delivery vehicles such as nanoparticles, and its toxicity profile for in vivo use has
not been adequately evaluated.

Nanoformulations of ICG, such as ICG-loaded PLGA nanoparticles or ICG-loaded
mesocapsules have demonstrated increased plasma circulation times and organ uptake in
mice (Saxena et al., 2006; Yaseen et al., 2009). Our group has shown that ICG entrapped
in nanoparticles can still produce hyperthermic cell killing (Tang et al., 2010), and we
have developed a multifunctional ICG-DOX-PLGA delivery system for image-guided
chemotherapy and hyperthermia (Manchanda et al., 2010). When exploring the effect of
the multifunctional system in cancer cell lines MES-SA, DX-5, and SKOV-3, we found
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that this delivery vehicle was able to circumvent multidrug resistance (MDR) in resistant
cells which expressed p-glycoprotein, and that the combination of hyperthermia and
chemotherapy resulted in improved cell killing compared to chemotherapy or
hyperthermia alone (Tang et al., 2010).

A possible alternative to the use of ICG, either in free dye form or as a nanoformulation,
is to explore the potential of other NIR dyes with similar optical and thermal generation
abilities but improved stability profiles. It would be desirable to have the ability to use
NIR-responsive molecules for imaging and hyperthermia while eliminating or
minimizing some of the problems that complicate ICG in in vivo applications (FernandezFernandez et al., 2012). An example of a NIR dye with strong similarities to ICG is the
commercially available dye IR820. The chemical structures of ICG and IR820 are very
similar, with the main difference being the addition of a chlorinated cyclohexene as an
intermediate ring in the structure of IR820 (Figure 1).

Figure 1. Molecular structures of indocyanine green (A) and IR820 (B). Note the structural similarity,
except for the chlorinated cyclohexene ring structure in IR820 which is absent in ICG.

The presence of this ring is expected to confer additional rigidity and stability to the
molecular structure compared to ICG, given that substituents within the polymethine
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chain will limit bond rotation (Levitus et al., 2011). The structural modification could
also possibly result in enhanced molecular stability by providing steric hindrance to
intermolecular aggregation processes. An additional advantage of the presence of the
chlorohexene is that it provides IR820 with more options for functional conjugation
through the chlorine group, which can result in more amenability to the creation of
multifunctional or targeted conjugates.

Several recent studies have applied IR820 dye or conjugates of the dye for in vivo
applications. Prajapati et al. used IR820 as a blood pool contrast agent to image tissue
injuries and tumors in mice, and estimated the dye clearance half-life to be similar to that
of albumin, approximately 35 hours, based on in vitro binding studies to albumin
(Prajapati et al., 2009). Pandey et al. conjugated IR820 with a photodynamic therapy drug
and studied the resulting conjugate in mice with IR820 being used exclusively for its
imaging role (Pandey et al., 2008). Masotti et al. conjugated IR820 with
polyethylenimine (PEI) for DNA binding applications and in vivo imaging (Masotti et al.,
2008). Thierry et al prepared poly(allylamine hydrochloride)-poly(acrylic acid) coated
magnetic iron oxide and gold nanoparticles, which were loaded with cisplatin as well as
with a conjugate of IR820 and PEI following the work done by Masotti and colleagues
(Thierry et al., 2009).

None of these studies exploited the inherent ability of IR820 to be used as a dual imaging
and hyperthermia agent, with all of them just focusing on its imaging properties. Prior to
our group’s work, there were also no previous reports of any efforts to perform a detailed
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in vitro characterization of IR820 in terms of thermal generation and optical
characteristics, or to study its toxicity in cellular systems, which should all have preceded
any in vivo applications (Fernandez-Fernandez et al., 2012). Additionally, there are to our
knowledge no reports of nanoconjugates of IR820 except for those resulting from this
dissertation.

1.2. Statement of Purpose and Specific Aims

The overarching goal of this project was to develop and characterize novel
nanoconjugates of IR820, and explore the potential of IR820 and its conjugates for
theranostic applications in cancer. As a result of the studies which are part of this
dissertation, our group was the first to characterize IR820 in terms of optical and thermal
generation properties; to compare IR820 properties to those of ICG for cellular
hyperthermia, cellular imaging, and in vivo imaging; and to formulate and characterize
long-circulating nanoconjugates of IR820 and polyethylene glycol (PEG) for theranostic
applications.

The following were the four objective-based specific aims:
1.2.1. Specific aim #1: IR820 in vitro characterization and theranostic applications
a.

Characterize the in vitro absorption and fluorescence behavior of IR820, and
compare it with ICG.

b.

Characterize the degradation of IR820 in aqueous solution under different
light and temperature conditions, and compare degradation kinetics with
those of ICG.
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c.

Compare in vitro cell imaging capabilities of IR820 with those of ICG.

d.

Compare the in vitro heat generation capability of IR820 after NIR laser
exposure with that of ICG.

e.

Characterize the in vitro cytotoxicity of IR820 on cancer cell lines MES-SA,
SKOV-3, and Dx5, and compare with ICG.

f.

Characterize the in vitro cytotoxicity of IR820 on cancer cell lines MES-SA,
SKOV-3, and Dx5 after NIR laser exposure, and compare with ICG.

Specific aim #1 is addressed in Chapter 3.

1.2.2. Specific aim #2: Formulation and characterization of ionic IR820 nanoconjugate
a.

Prepare IR820-PEG-diamine nanoconjugate using ionic interactions (IR820PDNCs)

b.

Characterize IR820-PDNCs in terms of physicochemical properties, dye
content, absorption/fluorescence properties, and stability in solution.

c.

Compare in vitro cell imaging capabilities of IR820-PDNCs with those of
IR820.

d.

Characterize the in vitro cytotoxicity of IR820-PDNCs on cancer cell lines
MES-SA, SKOV-3, and Dx5, and compare with IR820.

e.

Characterize the in vitro cytotoxicity of IR820-PDNCs on cancer cell lines
MES-SA, SKOV-3, and Dx5 after NIR laser exposure, and compare with
IR820.

Specific aim #2 is addressed in Chapter 4.
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1.2.3. Specific aim #3: Formulation and characterization of covalent IR820
nanoconjugate
a.

Prepare covalently-linked IR820-PEG-diamine nanoconjugate (IRPDcov)

b.

Characterize IRPDcov in terms of physicochemical properties, dye content,
absorption/fluorescence properties, and stability.

c.

Compare in vitro cell imaging capabilities of IRPDcov with IR820.

d.

Characterize the in vitro cytotoxicity of IRPDcov on cancer cell lines MESSA, SKOV-3, and Dx5, and compare with IR820.

e.

Characterize the in vitro cytotoxicity of IRPDcov on cancer cell lines MESSA, SKOV-3, and Dx5 after NIR laser exposure, and compare with IR820
cytotoxicity.

Specific aim #3 is addressed in Chapter 5.

1.2.4. Specific aim #4: Biodistribution studies of IRPDcov, IR820, and ICG
a.

Establish feasibility of using IRPDcov for in vivo imaging.

b.

Compare and contrast the biodistribution of IRPDcov, IR820, and ICG in an
in vivo model, using Matlab image analysis of fluorescent organ images 24
hours after i.v. injection.

c.

Compare and contrast biodistribution of IRPDcov, IR820, and ICG in an in
vivo model, by determining 24-hour quantitative content from organ
sampling.
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d.

Calculate and compare IRPDcov, IR820, and ICG pharmacokinetic
parameters, including plasma half-life, from blood sampling data collected at
4 different time points after i.v. injection.

Specific aim #4 is addressed in Chapter 6.
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CHAPTER 2: METHODOLOGY

This chapter describes the materials, methods, and protocols used in the experiments for
each of the specific aims. Some of the descriptions in this chapter have been previously
published as part of two manuscripts (Fernandez-Fernandez et al., 2012; Manchanda et
al., 2012). Permission has been obtained in writing from the journal editors to utilize
content from these publications in the dissertation manuscript, and copies of the
aforementioned permission emails are included in the appendices.

2.1. Materials and Methods for Specific Aim 1
2.1.1. Chemicals

ICG (MW 775, IR-125) was obtained from Fisher Scientific (Pittsburgh, PA). IR-820
(MW 849.47), methanol, formaldehyde, and dimethyl sulfoxide (DMSO) were purchased
from Sigma (St. Louis, MO).

2.1.2. Absorbance studies

Dye solutions were prepared in deionized water or in methanol and samples were placed
in 1.5 mL cuvettes. Samples were diluted down to the linear absorption range (< 3 A.U.),
and absorption spectra from 200 to 900 nm were recorded using a CaryWinUV
spectrophotometer (Varian/Agilent Technologies, Switzerland). Automatic blank
correction was performed using the appropriate solvent (water or methanol). The
instrument was allowed to warm up for 30 minutes before measurements, and operating
conditions were kept constant for all experiments.
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2.1.3. Fluorescent spectrum characterization
We prepared ICG and IR-820 solutions in deionized water at 20 μg/mL concentration,
and then performed serial dilutions to 0.078 μg/mL. The fluorescence spectrum of each
sample was measured using a Fluorolog-3 spectrofluorometer (Jobin Yvon Horiba,
Edison, NJ) in steady-state mode. The device was allowed to warm up for 30 minutes,
and then calibrated following manufacturer specifications for both the xenon lamp source
and the expected Raman spectrum of water. Samples were placed in 4.5-mL cuvettes and
measured immediately after preparation. For ICG and IR820 samples, we measured
emission after excitation at 785-nm, because this is the wavelength that is typically used
in ICG imaging systems. For IR820, we performed an additional set of measurements in
which we used the peak absorption wavelength for IR820 in water as the excitation
wavelength. We recorded spectral emission readings up to 900 nm, in 1-nm intervals.
Deionized water was used as a blank for background correction. The samples were
handled under reduced lighting conditions at all times to avoid photobleaching.

2.1.4. Effects of temperature and light on stability in aqueous solution

In order to characterize the optical stability of ICG and IR-820 in aqueous solution, we
prepared solutions of ICG and IR-820 as described in section 2.1.3., and selected a
concentration in the linear range, specifically, 0.625 μg/mL. Each sample (ICG or IR820)
was aliquoted into five borosilicate glass containers and each container was assigned to
one of five groups: (1) room temperature with constant direct light, (2) room temperature
covered with foil, (3) room temperature in the dark, (4) refrigerator, or (5) covered water
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bath at 42°C. A sample from each container was taken and measured at twenty-four hour
intervals, following the same calibration and measurement procedure. Measurements of
fluorescent intensity at the peak emission were done in triplicate. The instrument
operating conditions were kept constant throughout the four-day period.

Data analysis followed the procedure described by Saxena et al in their study of ICG
degradation in aqueous solution (Saxena et al., 2003). Briefly, data were plotted as
percent peak fluorescence remaining versus time in hours, and fit to a pseudo-first order
kinetics model to obtain the observed degradation rate constant k obs . From this, the
corresponding degradation half-time was calculated as shown in Equation 1 below.

t1/2 =

ln(2)
kobs

Equation 1

2.1.5. Stability in different solvents under constant light and temperature conditions

The stability of ICG and IR820 dissolved in DMSO or methanol over a period of four
days was studied by selecting a concentration in the linear range, specifically, 0.312
μg/mL, and placing a sample of each solution (ICG or IR820) at the chosen concentration
in a borosilicate glass container in the refrigerator at 4°C in the dark. Samples from each
container were measured at twenty-four hour intervals, following the same measurement
procedure detailed in section 2.1.4., but using methanol or DMSO as the calibration blank
as appropriate. Measurements were done in triplicate. The instrument operating
conditions were kept constant throughout the four-day period.
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2.1.6. Heat Generation Properties

A NIR Laser Module source (RLDH808-1200-5, Roithner Laserthchnik Gmbh, Vienna,
Austria) emitting at 808 nm with an output power of 1.0 Watts was used for the heat
generation studies. Details of the setup have been provided by Tang et al. (Tang et al.,
2009). Briefly, the laser module was fixed to a clamp to direct NIR light from above. A
heated stage insert (World Precision Instruments Inc, Sarasota, Florida) was placed on a
mobile stage positioned directly below the laser, and used to keep a 96-well plate
containing dye samples at a baseline temperature of 37°C. The laser, when operational,
was enclosed in a box to prevent external emission of the NIR light and to avoid air
circulation that would affect the temperature of the sample. The mobile stage (holding the
heated insert) had an extension arm to the outside of the box. The arm was used to move
the location of the well plates, thereby allowing individual wells to be exposed to the NIR
energy in succession one at a time without opening the box. We prepared 2.5 μM, 5 μM,
and 10 μM solutions of ICG and IR820. Each sample was added to three wells in a 96well plate sitting on the heated stage insert, and excited with the 808-nm laser at a power
of 1440 J/cm2 for 180 seconds. Temperature inside the well was measured with a
thermocouple for the duration of exposure, and the three well values for a given dye were
averaged.

2.1.7. Cytotoxicity with and without hyperthermia

The cytotoxic effect of ICG or IR820 with and without laser treatment was studied in
human ovarian carcinoma SKOV-3 cells, human uterine sarcoma MES-SA cells, and
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resistant human uterine sarcoma MES-SA/Dx5 (Dx5) cells. MES-SA is a chemotherapy
sensitive uterine sarcoma line, and Dx5 is its multidrug-resistant counterpart. Multi drug
resistance (MDR) in Dx5 cells is conferred by expression of membrane drug efflux
protein P-gp. The ovarian epithelial adenocarcinoma line SKOV-3 also shows MDR
properties, but in this case due to an inherent p53 deletion gene mutation. Therefore,
these cell lines may respond differently to targeted therapy and hyperthermia, and they
provide good models for testing of cancer treatment modalities. The cell lines, along with
McCoy’s 5A medium and fetal bovine serum (FBS) were purchased from ATCC
(Manassas, VA, USA). Dulbecco's Phosphate Buffered Saline (DPBS) and penicillin
were purchased from Sigma Aldrich.

The cells were cultured as monolayers in McCoy's 5A medium supplemented with 10%
fetal bovine serum (FBS) and 1% penicillin in a humidified atmosphere of 95% air and
5% CO2 at 37°C. For continuous culturing, cells were grown in plastic tissue culture
flasks, subcultured twice weekly, and used for experiments while in the exponential
growth phase. In the cytotoxicity experiments, cells were seeded into two 96-well plates,
labeled plate A and B, at 5,000–8,000 cells per well. The plates were incubated overnight
to allow for cell attachment.

On day 0, 24 hours after initial cell seeding, the cells in plate A were fixed and a
Sulphorhodamine B (SRB) assay was performed using a TECAN plate reader (TECAN
Systems Inc, San Jose California) at a wavelength of 530 nm to determine control growth
of untreated cells. The absorbance values of the wells containing the cells were
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background subtracted (from wells containing medium only) and averaged to give T 0 ,
defined as the initial amount of cells on day 0. Thus, plate A establishes a reference for
the number of cells at the same time the experimental treatment is introduced in plate B.

On day 0, at the same time plate A was fixed to provide the T 0 value, plate B was treated
with IR820 or ICG (final concentration of 0-10 µM). A final concentration of 0 µM
indicates that no dye was added to the wells. Next, the cells in plate B were incubated at
37°C for approximately 2 hours, after which half of the wells in plate B were subjected to
laser treatment for three minutes. For each concentration of dye (0-10 µM), half of the
wells received laser treatment. Thus, for the control cells where no dye was added, half of
the cells were exposed to laser. This provides a laser, no-dye control group. Plate B was
returned to a 37°C incubator for another 24 hours. On day 1 (i.e. 48 hours after initial cell
seeding and 24 hours after laser treatment), the cell protein amount was measured by the
SRB assay. Potential cross talk between wells was eliminated by not using adjacent wells
for cells that were exposed to laser treatment, thus ensuring that applying laser treatment
to one well would not cause a temperature increase in another well. The SRB absorbance
values were background subtracted to give T (absorbance of the treated cells) and C
(absorbance of control cells not exposed to laser or dye). All measurements were done in
four wells per treatment.

The following formulae were used to calculate net cell growth:
if T≥T 0 , net cell growth = (T-T 0 )/(C-T 0 );

Equation 2

if T<T 0 then net cell growth (or cell death) = (T-T 0 )/(T 0 ).

Equation 3
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T 0 is determined from SRB measurements in plate A, and represents the number of cells
at the time treatment was initiated. C is determined from SRB measurements in plate B
for the wells that were not exposed to either laser or dye, and T is the absorbance of the
treated wells (laser treatment, dye treatment, or both). Net growth was plotted against dye
concentration to show the toxicity effects as previously described in the literature (Monks
et al., 1991). Statistical analysis (α = 0.05) was performed using one-way ANOVA to
compare (1) treatment values with the control value and (2) laser treatment versus no
treatment for the same concentration of dye (0-10 μM).
2.1.8. Cellular imaging

SKOV3, MES-SA, and Dx5 cell lines were purchased from ATCC and cultured
following ATCC specifications with 10% FBS-supplemented McCoy's 5A medium in a
37°C humidified incubator at 5% CO2 level. D-poly coverslips, formalin and 24-well
tissue culture plates were purchased from Fisher Scientific (Pittsburgh, PA, USA). Cells
were seeded at a density of 4 x 104 cells per well (SKOV-3) or 1 x 105 cells per well
(MES-SA, Dx5) in a 24-well plate over Poly-D-Lysine pre-coated glass coverslips placed
in each well, and incubated overnight to reach confluence. The medium was removed and
replaced with 0.5 mL of 10 μM IR820 or ICG solution and incubated for 30 minutes at
37°C without light exposure.

After incubation, cells were washed 3X with DPBS and fixed with 4% formaldehyde for
15 minutes at 37°C, followed by 3X washing with DPBS. The coverslips were then
removed and mounted on precleaned glass microslides with prolong antifade
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reagent/mounting medium mixture. Then, the specimens were observed using a
fluorescent microscope (Olympus IX81, Japan) with a 60x water immersion objective
and images were recorded with a CCD camera. The same filter set (λex = 775nm and
λem = 845nm) was used for imaging of both fluorescence dyes. The CCD camera
settings and exposures times were the same for both dyes for a given cell line (1000 ms
for SKOV-3 and 4000 ms for MES-SA and Dx5). Green pseudo-color was added using
EZ-C1 software (Nikon, Melville, NY).

2.1.9. Rat model studies

An imaging system consisting of a Sanyo DL 7140-201S laser (80 mW, 785 nm) and a
Retiga 1300 CCD camera was used. The entire setup was covered by BK5 blackout
material. The power at the imaging plane ranged from 0.1-0.5 mW. An equimolar
solution of ICG or IR820 was prepared based on a dose of 0.24 mg/kg of body weight
(Rajagopalan, 2000) and an injection volume of 0.25 mL. Wistar rats (160-224 g, nine
weeks old) were purchased from Harlan (Indianapolis, IN), kept under standard housing
conditions and fed ad libitum. All protocols followed the regulations of the Institutional
Animal Care and Use Committee. Rats were randomly assigned to groups. On the day of
the experiment, the animals were first anesthetized by inhalation of isoflurane in a closed
chamber, and then injected intraperitoneally with a 40 mg/kg dose of pentobarbital. The
chest and abdomen were shaved, and the animal was placed in supine facing the imaging
setup. An image of the rat was obtained under white light illumination to determine the
position of the target and to focus the camera before dye injection. Then, the laser was
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turned on and another image was taken prior to dye injection to establish background.
Laser current was set to 60 mA.

After the white and background images were obtained, ICG or IR820 dye was injected
through the tail vein using a 3-way stopcock system connected to two syringes, one
containing the dye and another one containing saline solution to flush the tail vein after
injection. The camera started recording immediately before the injection, and 10-second
exposure images of the abdomen were recorded in series using QCapture Pro software for
at least 40 minutes or until the rat regained consciousness. An image focused on the chest
was also taken before removing the animal from the setup on the day of the injection.
Twenty four hours later, the rat was imaged again (abdomen and chest) using the same
imaging setup under the same operating conditions. The protocol was completed in 6 rats,
three per dye. Additionally, organs were carefully dissected and extracted after the 24hour imaging protocol was completed in the intact animal. The lungs, kidneys and liver
were then placed in black-coated Petri dishes and imaged using the same imaging setup.

Images were processed in Matlab to select a background-subtracted region of interest and
calculate the normalized intensity, R, as the ratio of total pixel intensity (pixel index) in
the region of interest to the area of the signal in μm2. Statistical analysis was performed to
compare average ratios for each dye (t-test, 95% confidence level)

Quantitative measurements were performed by dye extraction in DMSO following the
procedure detailed by Saxena et al for ICG (Saxena et al., 2006). Briefly, the organs were
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homogenized and then incubated for four hours in DMSO. After four hours, the samples
were centrifuged at 4,500 rpm for 5 minutes, the supernatant was collected, and sample
emission was measured in a spectrofluorometer after 785 nm excitation. Dye mass in μg
obtained from this measurement was normalized to homogenized organ mass in grams,
and statistical analysis was performed to determine significant differences in dye content
(t-test at 95% confidence level). Dye mass was determined from a standard calibration
curve.

2.2. Materials and Methods for Specific Aim 2
2.2.1. Chemicals

PEG-diamine (6 kDa), IR820, methanol, dimethylsulfoxide (DMSO > 99.9% reagent
grade) were purchased from Sigma-Aldrich (St. Louis, MO, USA).

2.2.2. Nanoconjugate preparation

To an aqueous solution of PEG-diamine (MW 6 kDa, 30 mg/5 ml), a solution of IR820
(8.4 mg/5 ml) dissolved in deionized water was added drop-wise over a period of 45
minutes through a 5-ml syringe with continuous stirring. The molar ratio was 1:2 PEGdiamine:IR820 based on available functional groups (two amines in PEG-diamine and
one sulfonate in IR820). The reaction mixture was allowed to stir at room temperature for
3 hours. The ionic complex between PEG-diamine and IR820 was achieved by
electrostatic interactions between the negatively charged sulphate groups of IR820 and
the positively charged amine groups of PEG-diamine (Figure 2). The solution was
centrifuged at 25,000 rpm for 30 minutes, the supernatant was discarded, and the
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nanoconjugates thus formed were washed 3x with deionized water (5 ml). The resulting
material was freeze-dried using the Freezone system (Labconco, Free Zone Plus 6) for 24
hours.

Figure 2. Reaction scheme and formulation of ionic IR820-PEG-diamine nanoconjugate (IR820-PDNCs).

2.2.3. Nanoconjugate characterization

Scanning electron microscopy (SEM) was used to verify size and uniformity of nanoplex
shape and size. Freeze-dried IR820-PDNCs were resuspended in distilled water and were
later dropped onto a silicon grid and dried under room temperature. The suspension was
vacuum-coated with gold for 3 minutes. The surface morphology of the samples was
observed under a scanning electron microscope (JEOL–JEM) operated at 15-keV pulse at
different resolutions.
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Nanoconjugate zeta potential was measured using a Zetasizer, Nano ZS (Malvern
Instruments, UK) employing a nominal 5-mW He–Ne laser operating at 633 nm
wavelength. The scattered light was detected at a 135° angle. The refractive index (1.33)
and the viscosity (0.89) of ultrapure water at 25°C were used for measurements.

The FTIR spectra of dried material was recorded using the Perkin–Elmer®Spectrum™
1000 FT-IR spectrometer (Perkin Elmer Inc., San Jose, CA), equipped with a
Universal ATR (attenuated total reflectance) sampling device containing diamond crystal.
Spectra were acquired and then processed with the Spectrum software. The spectra were
scanned at room temperature over the wave number range of 4000–400 cm−1, with a scan
speed of 0.2cm/s and accumulations at a resolution of 4 cm-1. Triplicates of each sample
were averaged to obtain an average spectrum. A background spectrum of air was scanned
under the same instrumental conditions before each series of measurements.

2.2.4. Dye content determination

The IR820 content in the freeze-dried nanoconjugates was determined by dissolving a
known amount of sample in DMSO, sonicating to ensure complete dissolution, and
performing serial dilutions in the fluorescence linear range. Sample fluorescence was
measured at peak emission after 785-nm excitation with a Fluorolog-3 spectrofluorometer
(Jobin Yvon Horiba, Edison, NJ, USA) under constant operating conditions. The amount
of IR820 in the samples was determined from a calibration curve of free IR820 in DMSO
after 785-nm excitation using blank subtraction.
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2.2.5. Characterization of absorption properties

We prepared samples of IR820, PEG-diamine, and IR820-PDNCs in deionized water at
100 μg/mL concentration, and performed serial dilutions in the linear range. The
concentration of IR820-PDNCs was normalized to dye content, and the concentration of
PEG-diamine was also normalized based on the corresponding proportion of IR820 and
PEG-diamine used in the formulation process. Sample absorption from 200 to 900 nm
was measured with a Cary UV spectrophotometer (Varian/Agilent Technologies,
Switzerland).

2.2.6. Characterization of fluorescence properties
We prepared samples of IR820 and IR820-PDNCs in PBS buffer at 100 μg/mL
concentration, and performed serial dilutions in the linear range. Fluorescence emission
from the samples was measured in 1-nm intervals after 690 nm-excitation, 785-nm
excitation, and 844-nm excitation. Samples were measured using a Fluorolog-3
spectrofluorometer (Jobin Yvon Horiba, Edison, NJ, USA). Fluorescent curves were
blank-subtracted and plotted versus emission wavelength.

2.2.7. Fluorescence stability studies

We prepared samples of IR820 and IR820-PDNCs in PBS buffer at concentrations in the
linear range, and measured their baseline fluorescence emission profile after 785 nm
excitation. Sample emission fluorescence was measured from 795 nm up to 850 nm, at 1nm intervals. The samples were measured in 4-mL cuvettes using a Fluorolog-3
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spectrofluorometer (Jobin Yvon Horiba, Edison, NJ, USA). Different aliquots from the
same sample batch were kept in the refrigerator and measured following the same
procedures 4 hours after preparation. The emission peak value was used to determine
changes from baseline and the percent remaining fluorescence intensity was calculated.
Statistical significance was determined by comparing percent remaining intensities using
a t-test with α = 0.05.
2.2.8. Cytotoxicity with and without hyperthermia

The cytotoxicity of four different treatments (IR820, IR820-PDNCs, IR820 plus laser,
and IR820-PDNCs plus laser) in cancer cell lines was studied using the SRB colorimetric
assay. Three different types of cancer cell lines (MES-SA, Dx5 and SKOV-3) were used
for cytotoxicity assessment. Cells were seeded onto 96-well plates at an approximate
density of 2x104 cells/well, and incubated overnight for attachment to the well, followed
by treatment with free IR820 or IR820-PDNCs. The SRB assay was performed 24 hours
post treatment to determine net cell growth. Tested IR820 concentrations ranged from 0
to 5 µM, where IR820 concentration equal to zero means that only DPBS and no drug
was added to the wells (control group). Tested IR820-PDNCs concentrations were
normalized to IR820 content in the particles so that the treatments were equivalent to
tested concentrations of free dye.

In order to test the effect of hyperthermia, some of the cells were incubated for one hour
with one of the following treatments: (1) 5 μM IR820, (2) IR820-PDNCs at
concentrations equivalent to 5 μM of IR-820, (3) 2.5 μM PEG-diamine (based on the
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molar ratio 1 PEG-diamine: 2 IR820 in the nanoplex formulation), or (4) only cell
medium. These cells were then exposed to NIR laser illumination for 3 minutes, and the
SRB assay was performed 24 hours post laser treatment. Temperature was measured with
a thermocouple, and experimental wells were separated from each other by at least one
empty well in all directions to avoid cross-effects. Data processing and analysis were as
described in section 2.1.7., with net growth values generated by normalizing the data
from each treatment to the growth of the control cells which were not exposed to IR820,
IR820-PDNCs, or laser. Statistical significance was identified by one-way ANOVA for
the difference among groups at the same treatment concentration, and between each
group and the control group. A p-value <0.05 was considered to be statistically
significant.

2.2.9. Cellular imaging

Lysine-coated coverslips were placed in each well of a 24-well plate. MES-SA, Dx5, and
SKOV-3 cells were seeded on the coverslip at a density of 1 × 105 cells, 1 × 105 cells and
5 × 104 cells per well respectively in McCoy’s 5A medium supplemented with 10% fetal
bovine serum (FBS) and 1% penicillin, and were grown overnight for attachment. On the
next day, the cell medium was removed and replaced with 5μM IR820 or equivalent free
dye content of IR820-PDNCs. Cells were incubated in the dark at 37° C for 2.5 hours and
then washed 3X with Dulbecco's phosphate buffered saline (DPBS). Then the cells were
fixed with 4% formaldehyde for 15 minutes at 37°C, followed by 3X washing with
DPBS. The coverslips were then removed and mounted on glass microslides with
antifade reagent/mounting medium mixture. The cells were then examined by
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fluorescence microscopy (Olympus IX81, Japan) with a 60X water-merged objective.
The fluorescence was imaged at λ ex (775 nm), λ em (845 nm) with an exposure time of
4000 ms, which is well below the 20,000 ms threshold for autofluorescence. A CCD
camera was used to capture the signals and the images were software-merged with
pseudo color. The fluorescence microscope settings were kept the same throughout the
experiment. Images were processed in Matlab to select a background-subtracted region of
interest and to calculate the normalized intensity, R, as the ratio of total pixel intensity
(pixel index) to signal area.

2.3. Materials and Methods for Specific Aim 3
2.3.1. Chemicals

PEG-diamine (6 kDa), IR820, methanol, dimethylsulfoxide (DMSO > 99.9% reagent
grade), and triethylamine (TEA) were purchased from Sigma-Aldrich (St. Louis, MO,
USA).

2.3.2. Nanoconjugate preparation

A mixture of PEG-diamine (MW 6 kDa, 30 mg/5 ml) and IR820 (9.4 mg/5 ml) in
methanol was refluxed for 4 hours in the presence of triethylamine (2 eq.). The molar
ratio was 1:2 PEG-diamine:IR820 based on available functional groups (two amines in
PEG-diamine and one chloro group in IR820). The reaction scheme is illustrated in
Figure 3, and involves covalent attachment of the amine group in PEG-diamine to the
cyclohexene in IR820 at the chloro-substituted position via nucleophilic substitution,
with displacement of the chlorine atom and production of triethylamine hydrochloride.
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After the reaction progressed to completion, the sample was concentrated and the residue
was dissolved in 5 ml of water, followed by dialysis against water using a MWCO 3.5
kDa for 24 hours. The nanoconjugates were freeze-dried using the Freezone system
(Labconco, Free Zone Plus 6) for 24 hours, and stored in powder form at 4oC for further
use. The reaction scheme was developed in consultation with Dr. Pradeep Kumar, from
the Institute of Genomics and Integrative Biology in India.

Figure 3. Reaction scheme and formulation of covalent IR820-PEG-diamine nanoconjugate (IRPDcov).

2.3.3. Nanoconjugate characterization

SEM pictures and zeta-potential measurements were obtained as described in section
2.2.3. H-NMR measurements were performed with the assistance of Tereza Vokata,
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graduate student at the FIU Chemistry Department. For H-NMR measurements, samples
of IR820, PEG-diamine, and IRPDcov were dissolved in deuterated methanol. The 1H
NMR spectra were recorded on a 400 MHz Avance Bruker NMR spectrometer using 240
scans. Acquired data was processed and analyzed using MestReNova software. Chemical
shifts were reported in parts per million (ppm) for 1H NMR on δ scale based on the
MeOD solvent peak (δ = 3.31 ppm) as an internal standard.
2.3.4. Dye content determination

The IR820 content in the freeze-dried nanoconjugates was determined by dissolving a
known amount of sample in DMSO, and following the procedures in section 2.2.4.

2.3.5. Fluorescence stability studies

We prepared samples of IR820 and IRPDcov in PBS buffer at concentrations in the linear
range, and measured their baseline fluorescence emission profile after 785 nm excitation.
The same procedures were followed as those described in section 2.2.5., except that
fluorescence measurements were taken for up to 72 hours after sample preparation.

2.3.6. Cytotoxicity with and without hyperthermia

The cytotoxicity of four different treatments (IR820, IRPDcov, IR820 plus laser, and
IRPDcov plus laser) was studied in cancer cell lines MES-SA, Dx5 and SKOV-3. The
procedures followed were as described in section 2.2.8., with the use of IRPDcov in lieu
of IR820-PDNCs.
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2.3.7. Cellular imaging
MES-SA, Dx5 and SKOV-3 cells were imaged after 4-hour exposure to either 5μM
IR820 or equivalent free dye content of IR820PDcov, following the same procedures
described in section 2.2.9.

2.4. Materials and Methods for Specific Aim 4

The methods used in the fulfillment of specific aim 4 are described and discussed in
complete detail in chapter 6. Briefly, thirty-six healthy ND4 Swiss-Webster outbred mice,
weighing between 25 and 30 grams, were purchased from Harlan (Indianapolis, IN),
housed at the FIU Animal Care Facility under a 12-hour light/dark cycle and fed ad
libitum. Mice were randomly assigned to one of twelve groups (n=3) based on optical
agent (ICG, IR820, or IRPDcov), and time point of data collection after injection (15
minutes, 30 minutes, 60 minutes, and 24 hours).

For time groups in the range of minutes, mice were anesthetized with i.p. pentobarbital
(100 mg/kg), shaved, placed supine on the imaging setup described in section 2.1.9.,
injected through the tail vein with their assigned agent, and imaged. At the predetermined
time point, a blood sample was obtained under anesthesia by heart puncture into the
ventricle, and the animal was then euthanized by removal of the heart.

For mice in the 24-hour groups, each animal was anesthetized with 40 mg/kg of i.p.
pentobarbital, injected with the assigned agent, and imaged. These mice were then
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returned to their cage alive until the 24 hour time point. After 24 hours, they were
anesthetized with pentobarbital (100 mg/kg) and imaged again under the same operating
conditions. After imaging, a blood sample was obtained by heart puncture, and organs
were carefully harvested for imaging and subsequent homogenization and dye extraction.
Organ and plasma dye content were calculated from spectrofluorometric measurements
of the samples using a previously created calibration curve of IR820 or ICG in DMSO at
785 nm excitation. Specific pharmacokinetic analysis of plasma data and the choice of
models for data fitting are both discussed in depth in chapter 6.
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CHAPTER 3: IR820 CHARACTERIZATION AND
THERANOSTIC APPLICATIONS

The purpose of specific aim #1 was to determine the feasibility of using IR820 as a
substitute for ICG in imaging and photothermotherapy applications, and to perform a
general characterization of IR820 that can serve as a foundation for these applications.
We performed an in vitro comparison of the two dyes with respect to their optical
properties, thermal generation properties, stability profiles, and toxicity effects on cellular
systems. Additionally, we directly compared in vivo imaging characteristics of ICG and
IR820 in a rat model. This work has been published as a full journal article (FernandezFernandez et al., 2012). Permission has been obtained in writing from the journal editors
to utilize content from this publication in the dissertation manuscript, and a copy of the
aforementioned permission email is included in the appendices.

Materials and methods for this specific aim were discussed in chapter 2.

3.1. Physicochemical Characterization
3.1.1. Absorbance studies

Figure 4 shows the absorbance curves of IR820 and ICG in deionized water and
methanol. In methanol, absorption peaks are located at 820 nm for IR820 and 779 nm for
ICG. In water, the IR820 peak shifts to 691 nm, whereas peak absorption for ICG occurs
at 784 nm. The observed hypsochromic shift in IR820 peak absorption in water versus
methanol has been reported to exist in some heptamethine cyanine dyes, possibly as a

42

result of intramolecular charge transfer (ICT) or excited-state proton transfer (Peng et al.,
2005). Considering this property, we expect that the absorption peak for in vivo
applications is likely to be located close to the 691 nm peak observed in water, and the
higher wavelength methanol peak would only be relevant for in vitro applications in nonphysiological solvents.

Figure 4. Absorbance spectra of IR820 and ICG in deionized water (solid) and methanol (dashed).

3.1.2. Fluorescent spectrum characterization

Figure 5 shows curves of fluorescence emission intensity versus wavelength for different
ICG (5A) and IR820 (5B) concentrations in deionized water after excitation at 785 nm.
Both dyes showed quenching for concentrations greater than 1.25 μg/mL, with similar
linear ranges for both IR820 and ICG. This value is consistent with Saxena's reports of
linearity for ICG aqueous solutions at concentrations below 2 μg/mL (Saxena et al.,
2003). Our results also show that, for a given concentration, IR820 has approximately ten
times lower fluorescent yield than ICG after excitation at 785 nm.
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A

B
Figure 5. Fluorescence spectra after 785-nm excitation of aqueous solutions of (A) ICG and (B) IR820.

Table 1 shows peak emission location for different concentrations of ICG and IR820. For
ICG, the peak emission wavelength is dependent on concentration, and more
concentrated samples show emission shifts toward longer wavelengths. In the case of
IR820, peak location was not as dependent on concentration and remained between 822
and 823 nm.

Emission Peak Location in nm, intensity
Concentration (μg/mL)

IR820

ICG

2.5

823 nm, 9.86E4

807 nm, 1.19E6

1.25

823 nm, 6.87E4

802 nm, 8.12E5

0.625

822, 3.36E4

802 nm, 3.62E5

0.3125

822, 1.09E4

800 nm, 1.35E5

Table 1. Emission Peak Location for Aqueous Solutions of ICG and IR820.
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Besides comparing the fluorescent behavior of IR820 and ICG after 785-nm excitation,
we also studied the fluorescence properties of IR820 upon excitation at its 691-nm peak
absorption in water. The profiles are shown in Figure 6 and are similar to those obtained
for IR820 aqueous solutions after excitation at 785 nm. Again, quenching occurs above
1.25 μg/mL, and peak emission is located at 822-823 nm. A slight increase in
fluorescence emission of approximately 13-16% was observed for the emission spectrum
after 691-nm excitation when compared with excitation at 785 nm.

Figure 6. Fluorescence spectra after 691-nm excitation of aqueous solutions of IR820.

The fluorescent emission profiles of IR820 show lower fluorescence intensities than ICG
for equivalent concentrations. This was observed after 785-nm excitation as well as after
691-nm excitation (at the optimal absorption peak of IR820 in water). The lower quantum
yield after 785-nm excitation is expected based on the almost 100-nm difference with the
absorption peak of IR820 in water. After 691-nm excitation, peak fluorescence intensities
are higher than those observed after 785-nm excitation, but still lower than those of ICG.
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Therefore, there must be a structural factor that contributes to this behavior. Most likely,
the observed phenomenon is related to the intrinsic low quantum yield of the
chlorohexene ring (Shimoda et al., 1979), as well as to the internal heavy atom effect by
which a chlorine atom within the structure typically results in decreased quantum yields
and fluorescent lifetimes (Mac et al., 2003).

An advantage of IR820 fluorescence emission is that peak location for fluorescent
emission has little dependence on concentration, in contrast with ICG where we observe
more variability and a shift towards lower wavelengths with decreasing concentration.
The predictability of peak location for IR820 could facilitate the design of imaging
systems targeting IR820 emission wavelengths and diminish some of the challenges that
may arise with concentration-dependent peaks in ICG.

3.1.3. Effects of temperature and light on stability in aqueous solution
Aqueous solutions of IR820 and ICG were exposed to different temperatures (4°C, room
temperature, and 42°C) and light conditions (dark room, covered with foil, or direct
exposure to light). The degradation profiles of IR820 and ICG solutions, as shown in
Figure 7 (different temperatures) and Figure 8 (different light levels), follow pseudo-first
order kinetics with exponential decay. Covering the samples with foil was comparable, in
terms of delaying degradation, to keeping them in a dark room. As expected based on the
presence of the mesochlorohexene ring that confers rigidity to the molecule, IR820
demonstrated higher stability than ICG in aqueous solution under all temperature and
light conditions, with degradation half-times approximately double those of ICG for a
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given experimental condition. This is illustrated in Table 2. The degradation half-times
for ICG in this study were consistent with those reported by other groups for this dye
(Saxena et al., 2003). Direct light exposure and high temperatures resulted in fast
degradation for both dyes and loss of smooth spectral features by day 4.

Figure 7. Effect of temperature on degradation of aqueous solutions of IR820 and ICG. Solid lines
correspond to IR820 and dotted lines correspond to ICG. Error bars are ± SD.

Figure 8. Effect of light on degradation of aqueous solutions of IR820 and ICG. Solid lines correspond to
IR820 and dotted lines correspond to ICG. Error bars are ± SD.
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IR820
Experimental

k obs

t

ICG
k obs

1/2

R
-1

conditions

(hour )

(hours)

Light, 22°C

0.028

24.75

Dark, 22°C

0.020

Dark, 4°C
Dark, 42°C

t

1/2

2

R2
-1

(hour )

(hours)

0.994

0.051

13.59

0.987

34.65

0.992

0.042

16.50

0.992

0.019

36.47

0.981

0.036

19.25

0.995

0.035

19.80

0.984

0.064

10.83

0.989

Table 2. Stability characterization of aqueous solutions of IR820 and ICG following a pseudo-first order
kinetics model.

Our results showing that IR820 is more stable in aqueous solution than ICG are
consistent with other literature reports that describe structure-function relationships for
fluorescent cyanine dyes (Lee et al., 2008). Lee’s group reported that increased rigidity
of the molecular structure of a dye results in enhanced stabilization of the molecule.
Interestingly, temperature seemed to not be as important as light exposure in determining
the degradation behavior of IR820 solutions. We did not observe any enhancement in
stability when IR820 solutions were kept at 4°C in the dark versus when samples were
stored at room temperature in the dark; however, there was a difference between the two
conditions for ICG. Therefore, light exposure seems to be the most important influencing
factor in degradation mechanisms of IR820, rather than temperature, unless temperatures
are as extreme as those of a water bath (42°C). At such elevated temperatures, heat
collisions increase significantly and the molecules tend to aggregate closer together,
leading to increased degradation of the fluorescence properties.
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3.1.4. Stability in different solvents under constant light and temperature conditions
ICG and IR820 were both stable in DMSO and methanol over a period of 4 days, with no
significant decrease in fluorescence intensity when comparing samples measured on day
1 versus samples measured on day 4 (p>0.05, paired t-test). Thus, both dyes showed
excellent stability in methanol and DMSO.

3.1.5. Hyperthermia properties

Figure 9 illustrates changes in temperature during 180 seconds of 808-nm laser exposure
for IR820 (Figure 9A) and ICG (Figure 9B), with a starting temperature of 37°C. For
equivalent concentrations, the peak temperature increase for IR820 was significantly
smaller than the increase observed in ICG (4-9% difference in peak temperature, p<0.05
for comparisons between equivalent dye concentrations).

A

B

Figure 9. Heat generation profile of wells containing IR820 (A) or ICG (B) when irradiated with NIR laser
for a total of 3 minutes.

Although IR820 did not generate peak temperatures as high as those of ICG after threeminute laser exposure, at 5 μM and 10 μM the IR820 temperatures were still within the
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hyperthermia range of 40-43°C that is able to selectively impact tumor cell growth.
Tumor cells are sensitive to temperatures in this range, whereas the growth of normal
cells is not affected until temperatures reach higher levels (Baronzio et al., 2006).
Although a higher concentration of IR820 will be needed to attain the same temperature
as ICG in hyperthermia applications, it is still feasible to achieve temperatures in the
desirable 40-43°C range with as little as 5 μM IR820.

Samples from the 5 μM stock solutions, kept at 4°C in the dark, were also tested 3 days
and 6 days after the initial experiment to investigate the stability of heat generation
properties after the dye is in solution. The hyperthermia properties of both dye solutions
when irradiated with 808-nm light are stable over a period of 3 days, with no significant
changes in peak temperature generation in terms of percent of original peak temperature
recorded on the day of preparation. After 6 days, there is a significant decrease in peak
temperature for both dyes (p<0.05 compared to the initial peak). Even though the
decrease is significant with respect to the initial time point, both dyes still reach peak
temperatures higher than 41°C after 6 days. The stability of hyperthermia generation
presents a stark contrast to the rapid decay of fluorescence properties in aqueous solution,
indicating that non-radiative processes such as heat generation show a different behavior
over time compared to radiative processes such as fluorescence.

3.2. Cellular Experiments

Cellular experiments included cytotoxicity experiments with and without hyperthermia,
as well as fluorescent cell imaging.
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3.2.1. Cytotoxicity experiments
Figures 10, 11, and 12 show the results of cytotoxicity experiments in SKOV-3, Dx5, and
MES-SA cells, respectively.

Figure 10. IR820 and ICG cytotoxicity and hyperthermia effects in SKOV-3 cells. * = significant
difference (p<0.05) versus control group; ** = significant difference (p<0.05) versus same concentration of
dye without laser.

Figure 11. IR820 and ICG cytotoxicity and hyperthermia effects in Dx5 cells. * = significant difference
(p<0.05) versus control group; ** = significant difference (p<0.05) versus same concentration of dye
without laser.
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Figure 12. IR820 and ICG cytotoxicity and hyperthermia effects in MES-SA cells. * = significant
difference (p<0.05) versus control group; ** = significant difference (p<0.05) versus same concentration of
dye without laser.

Net cell growth was normalized to a control group that was not exposed to either dye or
laser. NIR-laser treatment by itself without addition of IR820 or ICG did not affect cell
viability for any of the cell lines. In the presence of ICG or IR820, the cytotoxicity
profiles of SKOV-3 (Figure 10) and Dx5 (Figure 11) were very similar. In these two cell
lines, concentrations up to 10 µM IR820 or ICG without laser treatment did not cause
significant decreases in cell viability when compared to the control group that received
no dye and no laser treatment. In MES-SA cells (Figure 12), there was significant (p<
0.05) cell growth inhibition upon exposure to 5 µM or 10 µM IR820 dye without laser
treatment. This is likely due to the fact that MES-SA cells are more sensitive to
environmental stressors than the other two cell lines, which are resistant to chemotherapy.
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When compared to the group that received laser treatment only, laser treatment of cell
lines exposed to IR820 or ICG caused significant (p<0.05) cell growth inhibition at 5 µM
dye concentration, and significant cell growth inhibition or cell killing at 10 µM,
indicating that both dyes can cause hyperthermia that impacts cell viability. Additionally,
for all cell lines, when comparing the effects of a given dye concentration with and
without NIR-laser treatment, cell proliferation was significantly lower in the NIR laser
treatment group versus the dye-only group for both dyes at 5 and 10 µM.

Thus, our cytotoxicity data shows that both IR820 and ICG hyperthermia cause
significant cancer cell growth inhibition at 5 µM, and significant cell growth inhibition or
cell killing at 10 µM. There is no statistical difference in the effect on net cell growth
between IR820 and ICG hyperthermia for a given concentration, indicating that IR820 is
a good substitute for ICG in therapeutic applications of hyperthermia.

3.2.2. In vitro cell imaging
Figure 13 shows images of MES-SA, SKOV-3, and Dx5 cells after 30-minute incubation
with IR820 or ICG, at image exposure times well under the 20,000 ms threshold for
cellular autofluorescence. The level of fluorescent brightness for both dyes allows for
sensitive cell imaging of cancer cell lines, and IR820 images are very similar to those
obtained with ICG. Similar dye distributions were observed for all cell lines in the
fluorescence microscope images. Both dyes resulted in widespread cytoplasmic
fluorescence along with a localized perinuclear signal. The cell images show some areas
in the cytoplasm where the fluorescent intensity seems to be higher for both dyes. This
may be due to intravesicle storage of the dyes (Quarta et al., 2009), or binding to
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cytoplasmic proteins such as ligandin (Kaplowitz et al., 1975). Other researchers have
reported that the amphiphilic characteristics of ICG cause specific interactions with the
phospholipid bilayer (Desmettre et al., 2000), and the structural similarity of IR820 may
result in similar interactions.

Image intensities for cells exposed to IR820 and ICG were comparable, despite the fact
that our spectrofluorometer studies show smaller emission intensities for IR820 compared
to ICG at equivalent concentrations. An additional consideration is that, based on its
better stability in aqueous solution, it is possible that IR820 could show an advantage
over ICG in long incubation periods and longer imaging windows.

Figure 13. Cellular imaging after incubation with IR820 or ICG. A and D, SKOV-3 were incubated for 30
minutes with 10 μM IR820 and ICG respectively. B and E, Dx5 were incubated for 30 minutes with 10 μM
IR820 and ICG respectively. C and F, MES-SA were incubated for 30 minutes with 10 μM IR820 and ICG
respectively. λ ex = 775 nm and λ em = 845 nm. Objective magnification, 60X.
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3.3. In vivo Imaging Studies
Figure 14 shows sample abdominal images of a rat 40 minutes after i.v. injection with
IR820 (14A) or ICG (14B) and excitation with a 60 mA 785-nm laser module. Both dyes
accumulated primarily in the liver, which is consistent with literature reports for the
biodistribution of ICG (Jiao et al., 2000). As expected from the lower fluorescence
intensities observed during in vitro optical experiments, the intensity of the IR820 image
following injection was lower than for the ICG image at equivalent molar dosages. An
additional reason could be that our imaging system was optimized for ICG imaging with
excitation at 785 nm. It is important to consider, however, that in vitro profiles cannot
fully predict behavior in an in vivo environment, where protein and surface binding could
have a large effect on fluorescent properties (Mordon et al., 1998). Interestingly, despite
the initial larger signal for ICG, imaging the same animal after 24 hours resulted in
normalized intensities that were higher for IR820 (14C) than for ICG (14D).

Figure 14. Rat abdomen images 40 minutes after i.v. injection with IR820 (A) or ICG (B), and 24 hours
after injection with IR820 (C) or ICG (D). Image ratios indicate signal intensity normalized to area in μm2.
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Area normalized image intensities (n=3) for IR820 and ICG are shown in Table 3. The
quantitative measurements confirm that the abdominal ICG signal was significantly
stronger than the abdominal IR820 signal immediately after injection (p<0.05), but the
opposite was true 24 hours later.
Image intensity per area, R (1/μm2)
Image at 60 mA laser current

ICG (n =3)

IR820 (n=3)

Abdomen, 40 minutes after injection

11.49 ± 2.49 (*)

4.74 ± 0.52

Abdomen, 24 hours after injection

1.86 ± 0.52

5.79 ± 0.86 (*)

Liver, 24 hours after injection

7.01 ± 4.01

14.87 ± 2.90 (*)

Kidneys, 24 hours after injection

2.18 ± 0.48

9.52 ± 3.04 (*)

Lungs, 24 hours after injection

1.06 ± 1.84

4.10 ± 0.81 (*)

Table 3. Image intensity per area in μm2 for different locations and time points after IR820 and ICG
administration. Values are average ± standard deviation. (*) = significant difference between dye signals, p
<0.05, for a given location and time point.

Also, when the organs were extracted and imaged after 24 hours, as shown in Figure 15,
we can see that IR820 was present in liver, lungs and kidneys, whereas the ICG signal
was mostly limited to the liver. In Table 3, this qualitative observation is confirmed by
the area-normalized intensities, which are significantly higher (p<0.05) for IR820
compared to ICG in liver, lungs, and kidneys 24 hours after the animal was injected with
the dye.
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Figure 15. Rat liver, lung, and kidney images 24 hours after injection with IR820 or ICG. Ratios indicate
signal intensity normalized to area in μm2.

Table 4 shows the quantitative organ dye content data obtained after homogenization and
DMSO extraction.
Organ dye content (μg/g tissue)
ICG (n =3)

IR820 (n=3)

Liver

0.014 ± 0.009

0.819 ± 0.290 (*)

Lungs

0.021± 0.026

0.066± 0.018

Kidneys

0.005 ± 0.002

0.166 ± 0.020 (*)

Table 4. Organ dye content (μg/g tissue) 24 hours after injection. Values shown are average ± standard
deviation, and (*) = significant difference, p <0.05.

In accordance with the images shown above and the area-normalized intensities, organ
content of IR820 (μg/g tissue) was significantly higher (p<0.05) than ICG in liver and
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kidneys 24 hours post injection. For the lungs, IR820 content was higher than ICG
content, but the difference did not reach statistical significance (p = 0.066).

Our rat organ studies showed that both dyes are processed primarily in the liver, but
IR820 seems to significantly accumulate in the kidneys as well. Interestingly, when
images were taken from the chest area after 24 hours, there was a signal from IR820 but
not from ICG, indicating that IR820 may localize to the lungs to a larger extent than ICG.
The lung image data is consistent with this observation, and shows a significant
difference in intensity ratios for IR820 and ICG in the lungs (p<0.05). However, the
difference in lung dye content did not reach statistical significance (p = 0.066). In one of
the ICG experiments, small “hot spots” were observed in the lungs 24 hours after
injection, which may have been due to ICG aggregation in the blood resulting in lung
accumulation. There was no ICG detected in the lungs of the other two rats 24 hours after
injection. On the other hand, the lack of statistical significant could also be due to simple
individual variability between subjects, which is also the source of other differences
between fluorescent images.

In summary, after 24 hours we observed a stronger signal in the intact animal for IR820
compared to ICG, and both the organ images and quantitative dye content analysis show
that IR820 is present in higher amounts than ICG in liver, kidneys, and lungs. This may
result in an advantage over ICG for imaging studies by providing longer image collection
windows, and is consistent with data reported by Prajapati et al (Prajapati et al., 2009).
This group observed increases in IR820 fluorescence upon binding to serum albumin, and
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they estimated that IR820 would have an approximate clearance half-life of 35 hours in
mice based on the half-life of albumin and on images collected over a span of 8 days in
mice. They did not take plasma samples or perform pharmacokinetic analysis upon i.v.
injection. As we will discuss in chapter 6, our pharmacokinetic experiments in mice
confirmed the increased plasma half-life of IR820 when compared to ICG. Our studies in
mice support Prajapati’s estimates, as well as the results discussed in the current chapter
for the rat model.

3.4. Summary
IR820 could be an alternative to ICG in imaging and hyperthermia applications based on
its enhanced stability, feasibility of use for in vitro and in vivo imaging, and hyperthermia
generation properties. IR820 may be used under circumstances where longer image
collection times or more predictable peak locations are desirable, and even though it does
not elevate temperature as sharply as ICG for equimolar concentrations, IR820 is able to
generate a cytotoxic environment upon laser exposure than can inhibit the growth of
cancer cells, or even result in cell killing. The optimal dye concentration for dual in vivo
imaging and hyperthermia treatment would depend on dye toxicity, hyperthermia tumor
killing effect, plasma clearance and instrument sensitivity. Additional issues that must be
considered include in vivo attenuation, as well as accumulation at desired target sites such
as tumor areas. Potential approaches to solve these problems include targeted
formulations of the dye, nanoformulations which can take advantage of the EPR effect,
and endoscopic or orthoscopic delivery of light for imaging and inducing hyperthermia.
The presence of the chlorohexene ring makes IR820 more amenable to conjugation
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chemistry compared to ICG, and provides opportunities for preparation of conjugate
formulations of the dye. Since aggregation of dye molecules is an important mechanism
for degradation of cyanine dyes, covalent conjugation of IR820 to other moieties could
result in formulations with enhanced stability. Versatility in selecting the conjugation
moiety also opens opportunities for imparting different functionality or properties to the
molecule. The development of specific nanoformulations of IR820 to enhance target site
accumulation, exposure, and toxicity to cancer cells while providing longer windows for
imaging and therapy may have significant potential as a theranostic approach to cancer
management.
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CHAPTER 4: PREPARATION AND CHARACTERIZATION OF IONIC IR820PEG DIAMINE NANOCONJUGATES (IR820-PDNCs)

Clinical translation of NIR-imaging and hyperthermia approaches in cancer must
overcome the challenges presented by free dye formulations in terms of plasma
circulation times and non-specific biodistribution. Nanotechnology provides some
opportunities to improve in vivo stability and target delivery. Intrinsic characteristics of
nanoformulations such as size, surface moieties, and charge can be customized in order to
modify their interactions with circulating proteins and cellular membranes. Additionally,
due to their size, nanosize agents are less susceptible to reticuloendothelial system
clearance, and in general have improved in vivo penetration into tissues and cells (Brigger
et al., 2002; Xu et al., 2006). The enhanced permeability and retention (EPR) effect also
acts as a passive targeting mechanism allowing nanoformulations to accumulate
preferentially at tumor sites. Immune responses to circulating foreign objects can be
reduced by coating nanoformulations with polyethylene glycol (PEG), thus resulting in
improved plasma circulation times (Harris et al., 2001). PEG can also be utilized as a
linker for antibody conjugation, which opens the possibility of actively targeted therapy
to further reduce uptake in non-tumor areas and increase the efficacy and safety of these
nanoformulations.

Specific aim #2 focused on the development and characterization of ionic IR820-PEGdiamine nanoplexes (IR820-PDNCs), and on researching their potential use in localized
hyperthermia and imaging. The size and surface morphology of these nanoplexes were
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characterized by SEM, and the optical properties in solution were studied using
spectrofluorometry and spectrophotometry. We explored possible applications through in
vitro experiments with three different human cancer cell lines (MES-SA, Dx5, and
SKOV-3) to investigate the feasibility of using the nanoplexes as imaging agents, and to
determine whether this formulation retained the ability to induce hyperthermic cell
killing.

This work has been published as a full journal article (Manchanda et al., 2012).
Permission has been obtained in writing from the journal editors to utilize images and
content from this publication in the dissertation manuscript, and a copy of the
aforementioned permission email is included in the appendices.

Materials and methods for this specific aim were discussed in chapter 2.

4.1. Characterization of IR820-PDNCs

Nanoplexes of PEG-diamine and IR820 were formed by electrostatic interactions
between oppositely charged groups in PEG-diamine and IR820. Since IR820 is a
monosodium salt, 50% of the molecules will remain in acid form at physiological pH.
IR820-PDNCs size and morphology were characterized using SEM, which showed
nanoplexes of approximately 50-100 nm diameter (Figure 16). The zeta potential of
IR820-PDNCs was 2.0±0.9 mV. PEG-diamine charges are neutralized during
formulation, so the remaining charge arises primarily from the sodium salt charge of
IR820 in its acid form and from nitrogen moieties. These charges make the nanoplexes
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dispersible in aqueous solution, with PEG-mediated steric repulsion also playing a role in
enhancing water dispersibility by preventing complex aggregation.

Figure 16. SEM image of IR820-PDNCs.

Particle yield was 25% for a 6k-PEG diamine formulation. IR820-PDNCs fluorescent dye
content was determined by spectrofluorometry to be approximately 0.125 mg IR820/mg
IR820-PDNCs. Samples of IR820-PDNCs were also analyzed by FTIR, ν = 1395 cm− 1
(C-S stretching), 1055 cm− 1 (C-O-C stretching), 894 cm− 1 (C-Cl stretching on
conjugated dienes). These characteristic peaks indicate the participation of PEG-diamine
as well as IR820 in the complex driven by electrostatic interactions. Although ionic
formulations may not be as stable as a covalent linkage, ionic formulations have been
used to provide improved delivery of therapeutic agents to cells (Nimesh et al., 2006),
indicating that they have potential for clinical translation. Molecules coupled by
electrostatic interactions typically maintain their native structure and activity, thus
preserving their biological function (Wu et al., 2011). Ionic formulations may also
present physiological advantages in terms of enhanced ion exchange processes or
enhanced degradation after cellular internalization (Nimesh et al., 2006). Additionally,
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many ionic formulations can be readily converted into covalent interactions through the
use of coupling agents or linkers. The study of IR820-PDNCs can provide valuable
information as to whether IR820 remains optically and thermally active when in close
proximity to other molecules, and to determine whether molecular interactions impact its
ability to function as a theranostic agent.

4.1.1. Absorbance studies

The UV-visible spectra of IR820, PEG-diamine and IR820-PDNCs are shown in Figure
17. Concentrations of PEG-diamine and IR820 were chosen based on molar ratios used in
the formulation of the nanocomplexes, and IR820-PDNCs concentration was chosen to
approximately match the concentration of the IR820 solution given the previously
estimated dye content (0.125 mg IR820/mg IR820-PDNCs).

Figure 17. Absorption spectra of IR820 (solid black), IR820-PDNCs (dashed black) and PEG-diamine
(gray) in deionized water.

66

IR820-PDNCs displayed three characteristic absorption peaks located at 690, 785, and
844 nm, between 0.677 and 0.906 A.U. at 6.25 μg/mL dye concentration. There were no
peaks above 0.01 A.U. between 200 and 900 nm for PEG-diamine at 24 μg/mL. The free
dye spectrum showed a single peak at 688 nm with almost the same absorption intensity
as the IR820-PDNCs solution. Therefore, the absorption spectra confirmed the validity of
the spectrofluorometric dye content determination, based on the close match for the 688690 nm peak. The other two peaks are unique to the nanoplex formulation and reflect
additional vibrational transitions, which may stem from interactions between functional
groups within the conjugate lattice, or from intermolecular hydrogen bonding (Mansoori
et al., 2010)

4.1.2. Fluorescence properties of IR820-PDNCs

Excitation of IR820-PDNCs at 690 nm or 844 nm did not produce a significant
fluorescence emission. There is probably translation of excitation energy into heat or
vibrational energy at these wavelengths. After 785-nm excitation, the nanocomplexes
demonstrated fluorescent emission. A representative fluorescence emission spectrum of
IR820-PDNCs after 785-nm excitation is shown in Figure 18 along with the
corresponding profile for IR820 at comparable dye content. The shape of the two profiles
is quite similar, although the emission peak intensity is about 15% lower for IR820PDNCs than IR820. The slight reduction in fluorescence intensity may be a result of
interactions with the buffer solvent, changes in electronic excitation energy transfer
mechanisms after the dye becomes part of the nanoplex lattice, absorption of
fluorescence emission at secondary absorption peaks, or perhaps a combination thereof.
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Figure 18. Fluorescence spectra of IR820 and IR820-PDNCs in phosphate buffered saline.

4.1.3. Fluorescence stability studies

IR820-PDNCs and IR820 solutions in buffer were measured 4 hours after preparation to
determine the percent remaining fluorescent intensity compared to baseline. IR820PDNCs showed a significantly (p<0.05) higher percent remaining intensity (68.9%)
compared to IR820 (58.9%) after 4 hours. This indicates that the ionic interactions within
the nanoplex lattice conferred added stability and protected the dye from degradation.

4.2. Cell Imaging Studies

Figure 19 shows fluorescence microscopy images of Dx5, SKOV-3 and MES-SA cell
lines after 2.5 hours incubation at 5 μM concentration of IR820 and IR820-PDNCs at
equivalent dye content. This concentration was chosen based on our previous cellular
studies with IR820 (Fernandez-Fernandez et al., 2012). In all three cell lines, intense
fluorescence was observed inside the cells after 2.5 hour incubation with IR820 or IR820-
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PDNCs, indicating that both the free dye and the nanoplexes were capable of entering the
cells. However, the images taken after IR820-PDNCs incubation showed higher
normalized intensity ratios than those taken after incubation with equivalent
concentrations of IR820, especially in SKOV-3 and Dx5. Normalized intensity ratios for
IR820-PDNCs were 2.1 times larger than for IR820 in SKOV-3 (R = 2.6 for IR820
versus R= 5.6 for IR820-PDNCs) and 1.7 times larger in Dx5 (R = 3.8 for IR820 versus
R = 6.5 for IR820-PDNCs). In MES-SA, the ratio showed a moderate increase (R= 5.7
for IR820 versus R = 6.9 for IR820-PDNCs).

Figure 19. Cellular imaging of Dx5 (A, B), SKOV-3 (C,D) and MES-SA cells (E,F) after 2.5 hour
incubation with 5 μM dye content of IR820-PDNCs (top) or IR820 (bottom); 60x, exposure time 4000 ms.

It is possible that the presence of PEG resulted in enhanced cell membrane interaction
and increased internalization compared to free dye, as PEG has been reported to mediate
solubilization of nanoformulations in the lipid bilayer. This results in enhanced solubility
in cell membranes and increased non-specific cellular uptake (Yamazaki et al., 1990;
Zhang et al., 2002). High concentrations of PEG in close proximity to cellular
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membranes create osmotic stress and osmoelastic coupling, which result in membrane
instability, enhanced leakiness and PEG-induced fusion vesicles without the need for
direct contact with PEG (Yamazaki et al., 1990). It is possible that exposure of cells to
IR820-PDNCs creates such an effect based on the osmotic effects of PEG, even if some
of the charge was neutralized during nanocomplex formation.

4.3. Cytotoxicity Studies without Hyperthermia

SKOV-3, Dx5 and MES-SA cells were chosen to study the cytotoxic effect of IR820 and
IR820-PDNCs on tumor cells using the SRB assay. The cells were incubated with
increasing concentrations of IR820 or IR820-PDNCs for 24 hours up to a maximum dose
of 5 μM IR820 content, in order to compare the toxicity profile of the nanoplexes and the
free dye. Figure 20 shows net cell growth following incubation with IR820 or IR820PDNCs for SKOV-3, Dx5, and MES-SA.

There was no significant difference in net cell growth between the IR820 group and the
IR820-PDNCs group for equivalent dye concentrations for any cell line. In SKOV-3 and
Dx5, there was also no significant cytotoxicity for any concentration of IR820 or IR820PDNCs compared to the control group which was not exposed to dye. On the other hand,
MES-SA cells showed significant (p<0.05) 17-25% cell growth inhibition at 5 μM
concentrations of either treatment, consistent with our prior observations discussed in
chapter 3, and again likely due to the fact that MES-SA cells are more sensitive to
environmental stressors than the other two cell lines, which are resistant to chemotherapy.
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Figure 20. Cytotoxicity of IR820-PDNCs or IR820 in cancer cell lines. Bars represent net cell growth after
24-hour exposure, n = 3 experiments, 4 wells per treatment. * = significant difference (p<0.05) versus
control (0 μM) group.

We also performed studies with exposure to (1) dye content of 25 μM, which resulted in
> 50% growth inhibition in all three cell lines for both IR820 and IR820-PDNCs; and (2)
PEG-diamine at 50 μM concentration, which is 20 times higher than the concentration of
PEG-diamine in nanoplexes containing 5 μM of IR820, and showed no toxicity in any of
the cell lines. The overall cytotoxicity results indicated that IR820-PDNCs have a toxicity
profile comparable to the free dye, and they can be safely used up to at least 5 μM, which
is within the applicable range for biological studies such as imaging.

4.4. Hyperthermia Studies

Our previous work has shown the ability of IR820 to induce hyperthermic cell growth
inhibition and cell killing (Fernandez-Fernandez et al., 2012). We tested IR820-PDNCs
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to determine whether the dye within the nanoplex still retained the ability to generate heat
when exposed to an 808-nm NIR laser. At a laser fluence rate of 8 W/cm2, a solution of
0.034 mg/ml IR820-PDNCs (containing 5 μM IR820) caused an increase in temperature
from 37°C to 42.5°C after 3 minutes of exposure. This temperature is within the range
used for localized hyperthermia aiming to affect tumor cells while sparing healthy cells..
Research has shown that moderate hyperthermia (41-43 °C) is able to cause significant
tumor cell growth inhibition but does not greatly affect healthy cells. The reason for this
differential behavior upon hyperthermia exposure is that cancer cells have mechanisms
that inhibit oxidative metabolism which are specifically activated by temperatures in this
range (Cavaliere et al., 1967; Luk et al., 1980; Tang et al., 2009). We also tested PEGdiamine by itself, which did not result in significant changes in temperature after 3minute laser exposure compared to wells containing medium only. Therefore,
hyperthermia generation stems from the IR820 portion of the nanoplexes.

Nanoplex-induced hyperthermia may have the potential to enhance toxicity compared to
free dye based on factors unique to the nanoformulation such as size, charge, enhanced
interaction with cell membranes, or overall increased internalization of the nanoplexes. In
order to study the effects of nanoplex hyperthermia on cellular systems, we tested MESSA, Dx5 and SKOV-3 cell proliferation with and without laser irradiation. The results are
shown in Figure 21. All groups were normalized to the control group not exposed to dye
or laser. As discussed in chapter 3, there was no significant effect of laser exposure on
cell growth without exposure to dye. Cell growth was significantly inhibited in all three
cell lines by both IR820 and IR820-PDNCs when exposed to laser. In MES-SA and Dx5
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cell lines, IR820-PDNCs hyperthermia resulted in significantly higher cytotoxicity (p<
0.05) compared to IR820. In SKOV-3 cells, IR820-PDNCs hyperthermia produced
higher cytotoxicity than free dye, but not enough to reach statistical significance.

Figure 21. Cytotoxicity of hyperthermia treatment with 5 μM dye content of IR820 or IR820-PDNCs, n = 3
experiments, 4 wells/experiment. All groups are normalized to the control group not exposed to dye or
laser. There was no significant effect of laser exposure per se without IR820-PDNCs or IR820, and there
was no significant effect of PEG-diamine exposed to laser. * = significant difference (p<0.05) versus nonlaser group, **= significant difference (p<0.05) between laser groups.

Based on the cell imaging results displayed in Figure 19, IR820-PDNCs were
internalized more readily by cells than the free dye. This is consistent with the increased
cytotoxicity effect of the hyperthermia treatment that can be observed in Figure 21.
Enhanced internalization would result in improved ability to cause damage to cells by
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heat generation compared to free dye. It is interesting to note that the enhanced cytotoxic
effect reached statistical significance in MES-SA and Dx5 cell lines, but not in SKOV-3.
This could be due to inherent insensitivity to hyperthermia in SKOV-3. These cells have
a p53 deletion gene mutation that affects their response to different cytotoxic agents. It is
possible that the mutation may also influence apoptotic response to hyperthermia events,
although this issue is controversial.

Some studies suggest that hyperthermia-induced apoptosis is independent of p53
mutations (Fukami et al., 2004; Sturm et al., 2006). Tang et al found that simultaneous
use of ICG hyperthermia and doxorubicin chemotherapy in SKOV-3 resulted in increased
cell growth inhibition compared to chemotherapy alone or hyperthermia alone. This
would seem to indicate that these cells can still be affected by hyperthermia despite the
p53 mutation (Tang et al, 2009). However, other groups have reported that the process of
apoptosis after hyperthermia can depend on p53 expression and may occur in both a p53dependent and -independent manner (Goto et al., 1999; Ohnishi et al., 2008; Seo et al.,
1999; Takahashi et al., 2003). Further studies are needed to clarify the effect of p53 gene
deletion on the response to localized NIR-dye mediated hyperthermia.

Given that PEG diamine has the potential to generate peroxide radicals upon light
exposure, it may create increased oxidative stress in cells exposed to a laser. In order to
explore this possibility, we also tested a PEG-diamine only group. MES-SA, Dx5, and
SKOV-3 were exposed to 2.5 µM PEG-diamine (based on the molar formulation ratio of
1:2 PEG-diamine to IR820) and received laser treatment as previously described. Our
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results showed that there were no significant differences in cell growth (p>0.05) for the
PEG plus laser group compared to either the control group that was not exposed to PEGdiamine, or to the group that received PEG-diamine without laser treatment. Therefore,
PEG-diamine by itself did not cause oxidative stress levels able to significantly affect cell
growth after laser exposure.

Our results showed an enhanced effect of IR820-PDNCs hyperthermia in Dx5 and MESSA cells. Increases in cell internalization may play a role in explaining this difference,
but the co-localization of PEG-diamine and IR820 could also be an important factor to
consider. Although PEG-diamine free radical generation is not sufficient to significantly
affect cell growth, research has shown that the presence of free radical generators can
enhance the effect of hyperthermia, because some mechanisms of cell death in
hyperthermia are tied to oxidative stress responses (Li et al., 2001; Skibba et al., 1997;
Wada et al., 2005; Yuki et al., 2003).

In the case of IR820-PDNCs, which contain both IR820 and PEG-diamine, it is possible
that simultaneous increased temperature (from IR820 hyperthermia) and free radical
generation (from PEG-diamine laser exposure) could have resulted in enhanced
cytotoxicity compared to free dye hyperthermia for Dx5 and MES-SA cells, even if free
radical generation from PEG-diamine in isolation does not have an effect. This could
provide an advantage to the nanoplex formulation with respect to individual therapies by
achieving codelivery and combined action of its components.
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4.5. Summary

Under this specific aim, we successfully prepared ionic nanocomplexes of IR820 and
PEG-diamine (IR820-PDNCs), characterized their optical properties and investigated
their cytotoxicity with and without laser exposure in cancer cell lines MES-SA, SKOV-3
and Dx5. The nanoplexes were able to generate a cytotoxic hyperthermia effect, as well
as to emit a fluorescence signal that can be used for imaging. This formulation can
potentially provide an advantage over the use of free agents by enhancing cell uptake,
allowing simultaneous co-localization of imaging and therapy, and accentuating the
cytotoxic effect of hyperthermia. Modifications in nanoplex formulation to create
covalent conjugates could improve on the stability of the lattice and result in nanosize
conjugates that may be used in in vivo applications.

76

Chapter 4 References
Brigger, I., C. Dubernet, et al. (2002). Nanoparticles in cancer therapy and diagnosis.
Adv. Drug Delivery Rev. 54(5): 631-651.
Cavaliere, R., E. C. Ciocatto, et al. (1967). Selective heat sensitivity of cancer cells.
Biochemical and clinical studies. Cancer 20(9): 1351-1381.
Fernandez-Fernandez, A., R. Manchanda, et al. (2012). Comparative study of the optical
and heat generation properties of IR820 and indocyanine green. Mol Imaging
11(2): 99-113.
Fukami, T., S. Nakasu, et al. (2004). Hyperthermia induces translocation of apoptosisinducing factor (AIF) and apoptosis in human glioma cell lines. J. Neurooncol.
70(3): 319-331.
Goto, A., K. Shomori, et al. (1999). Hyperthermia-induced apoptosis occurs both in a p53
gene-dependent and -independent manner in three human gastric carcinoma cell
lines. Oncol. Rep. 6(2): 335-339.
Harris, J. M., N. E. Martin, et al. (2001). Pegylation: a novel process for modifying
pharmacokinetics. Clin. Pharmacokinet. 40(7): 539-551.
Li, F. J., T. Kondo, et al. (2001). Enhancement of hyperthermia-induced apoptosis by a
free radical initiator, 2,2'-azobis (2-amidinopropane) dihydrochloride, in human
histiocytic lymphoma U937 cells. Free Radic Res 35(3): 281-299.
Luk, K. H., R. M. Hulse, et al. (1980). Hyperthermia in cancer therapy. West J Med
132(3): 179-185.
Manchanda, R., A. Fernandez-Fernandez, et al. (2012). Nanoplexes for cell imaging and
hyperthermia: in vitro studies. J Biomed Nanotechnol 8(4): 686-694.
Mansoori, N., K. S. Brandenburg, et al. (2010). A Comparative Study of Two FolateConjugated Gold Nanoparticles for Cancer Nanotechnology Applications.
Cancers 2: 1911-1928.
Nimesh, S., A. Goyal, et al. (2006). Polyethylenimine nanoparticles as efficient
transfecting agents for mammalian cells. J. Control. Release 110(2): 457-468.
Ohnishi, T., A. Takahashi, et al. (2008). p53 Targeting can enhance cancer therapy via
radiation, heat and anti-cancer agents. Anticancer Agents Med. Chem. 8(5): 564570.

77

Seo, Y. R., M. L. Smith, et al. (1999). Mild hyperthermia-induced apoptosis is dependent
on p53 in human lymphoid cells. Res. Commun. Mol. Pathol. Pharmacol. 104(3):
285-292.
Skibba, J. L. and E. A. Gwartney (1997). Liver hyperthermia and oxidative stress: role of
iron and aldehyde production. Int J Hyperthermia 13(2): 215-226.
Sturm, I., B. Rau, et al. (2006). Genetic dissection of apoptosis and cell cycle control in
response of colorectal cancer treated with preoperative radiochemotherapy. BMC
Cancer 6: 124.
Takahashi, A., I. Ota, et al. (2003). p53-dependent hyperthermic enhancement of tumour
growth inhibition by X-ray or carbon-ion beam irradiation. Int J Hyperthermia
19(2): 145-153.
Tang, Y. and A. J. McGoron (2009). Combined effects of laser-ICG photothermotherapy
and doxorubicin chemotherapy on ovarian cancer cells. J. Photochem. Photobiol.
B 97(3): 138-144.
Wada, S., Z. G. Cui, et al. (2005). A hydrogen peroxide-generating agent, 6-formylpterin,
enhances heat-induced apoptosis. Int J Hyperthermia 21(3): 231-246.
Wu, S., A. Buthe, et al. (2011). Organic-Soluble Enzyme Nano-Complexes Formed by
Ion-Pairing with Surfactants. Nanoscale Biocatalysis - Methods in Molecular
Biology 743: 51-63.
Xu, Z. P., Q. H. Zeng, et al. (2006). Inorganic nanoparticles as carriers for efficient
cellular delivery. Chem. Eng. Sci. 61(3): 1027-1040.
Yamazaki, M. and T. Ito (1990). Deformation and instability in membrane structure of
phospholipid vesicles caused by osmophobic association: mechanical stress model
for the mechanism of poly(ethylene glycol)-induced membrane fusion.
Biochemistry 29(5): 1309-1314.
Yuki, H., T. Kondo, et al. (2003). A free radical initiator, 2,2'-azobis (2-aminopropane)
dihydrochloride enhances hyperthermia-induced apoptosis in human uterine
cervical cancer cell lines. Free Radic Res 37(6): 631-643.
Zhang, Y., N. Kohler, et al. (2002). Surface modification of superparamagnetic magnetite
nanoparticles and their intracellular uptake. Biomaterials 23(7): 1553-1561.

78

CHAPTER 5: PREPARATION AND CHARACTERIZATION OF COVALENT
IR820-PEG DIAMINE NANOCONJUGATES (IRPDcov)

Specific aim #3 focused on the development and characterization of covalent IR820PEG-diamine nanoconjugates (IRPDcov), and on researching their potential use in
localized hyperthermia and imaging. The size and surface morphology of these
nanoconjugates were characterized by SEM, conjugation was confirmed by H-NMR, and
the optical properties in solution were studied using spectrofluorometry and
spectrophotometry. We explored possible applications through in vitro experiments with
three different human cancer cell lines (MES-SA, Dx5, and SKOV-3) to investigate the
feasibility of using the nanoconjugates as imaging agents, and to determine whether this
formulation retained the ability to induce hyperthermic cell killing. Promising results led
to in vivo testing, which is discussed under chapter 6 as specific aim #4.

The work described in chapters 5 and 6 is currently a manuscript in preparation for
submission to the Journal of Biomedical Optics.

Materials and methods for specific aim # 3 were discussed in chapter 2.

5.1. Characterization of IRPDcov

Covalent nanoconjugates of PEG-diamine and IR820 were prepared by mixing IR820
and 6kDa PEG-diamine (2:1 ratio) in methanol and refluxing for 4 hours in the presence
of triethylamine (2 eq.), with displacement of the chlorine atom by nucleophilic
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substitution and production of triethylamine hydrochloride. Then, the solvent was
removed, the residue dissolved in water, dialyzed against water, freeze-dried, and stored
in powder form at 4ºC for further use. IRPDcov size and morphology were characterized
using SEM, which showed nearly-spherical uniformly distributed nanoconjugates of
approximately 150 nm diameter (Figure 22). Hydrodynamic diameter (DLS)
measurements were around 348 nm, whereas the SEM image showed smaller particle
sizes. This difference is expected because DLS measures hydration and swelling of the
conjugates in an aqueous phase, which results in increased diameters compared to the dry
sample in SEM. The zeta potential of IRPDcov was -0.4±0.3 mV, due to charge
neutralization during formulation. The nanoconjugates are soluble in aqueous solution,
and PEG-mediated steric repulsion assists in preventing the formation of aggregates, with
a solubility limit of approximately 2 mg IRPDcov/mL in deionized water.

Figure 22. SEM image of IRPDcov.

Particle yield was 74% for a 6k-PEG diamine formulation. IRPDcov fluorescent dye
content was determined by spectrofluorometry to be approximately 0.113 mg IR820/mg
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IRPDcov. Samples of IRPDcov in deuterated methanol were also analyzed by H-NMR,
which confirmed conjugate formation. Figure 23 illustrates the H-NMR spectrum of the
conjugate denoting the main identifiable peaks. The conjugate spectrum contains peaks
contributed both from IR820 and PEG-diamine, which suggests that we have indeed
made the conjugate. Any unreacted IR820 would have been removed during the dialysis
process, so the presence of aromatic peaks (in the region between 7 and 9 ppm) indicates
that the covalent linkage between IR820 and PEG-diamine was successful. It is important
to note that there are small extra peaks in the spectrum that indicate that the sample is not
completely pure, however, this can be attributed to the fact that IR820 is only available as
a commercial grade chemical.

Figure 23. H-NMR spectrum of IRPDcov in deuterated methanol.
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5.1.1. Absorbance studies

The UV-visible spectra of IR820, PEG-diamine and IRPDcov are shown in Figure 24.
Concentrations of PEG-diamine and IR820 were chosen based on molar ratios used in the
formulation of the nanocomplexes, and IRPDcov concentration was chosen to
approximately match the concentration of the IR820 solution given the previously
estimated dye content (0.113 mg IR820/mg IRPDcov).

Figure 24. Absorption spectra of IR820 (solid black), IRPDcov (dashed black) and PEG-diamine (gray) in
deionized water.

IRPDcov displayed a bathochromic main absorption peak shift compared to IR820
(IRPDcov λ max = 696 nm, IR820 λ max = 688 nm) as well as a shift in the secondary
absorption peak (located at 836 nm for IRPDcov versus 815 nm for IR820). These shifts
can be attributed to the formation of an extended π system by the conjugation process.
There was also an overall broadening of the spectral profile. Increased absorption and
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scattering within the environment of the nanoconjugate may explain the spectral
observations. There were no peaks above 0.01 A.U. between 200 and 900 nm for PEGdiamine at 24 μg/mL. The free dye spectrum showed a single peak at 688 nm with almost
the same absorption intensity as the IRPDcov solution, confirming our dye content
determination.

5.1.2. Fluorescence properties of IRPDcov

A representative fluorescence emission spectrum of IRPDcov after 785-nm excitation is
shown in Figure 25 along with the corresponding profile for IR820 at comparable dye
content. After 785-nm excitation, the peak emission for IRPDcov was located at 822 nm,
with fluorescence intensity 6% smaller than IR820. The slight reduction in fluorescence
intensity may be due to absorption of emitted fluorescence at secondary absorption peaks.

Figure 25. Fluorescence spectra of IR820 and IRPDcov in phosphate buffered saline.

In the case of IR820-PDNCs which were formulated by ionic interactions, fluorescence
intensity of the conjugates was approximately 15% less than that of free dye. Therefore,
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the covalent formulation demonstrates improved fluorescence with respect to the ionic
formulation, likely by reducing unwanted interactions between IR820 and the buffer
solvent.

5.1.3. Fluorescence stability studies

IRPDcov and IR820 solutions in buffer were measured up to 72 hours after preparation to
determine the percent remaining fluorescent intensity compared to baseline. Samples
were kept at 4°C in the dark. The decrease in fluorescence from baseline after 72 hours
was significantly lower for IRPDcov (39.9% decrease) compared to IR820 (80%
decrease), p<0.05. This indicates that covalent conjugation provides significant
stabilization to the dye, likely as a result of increased rigidity of the IR820 molecule by
incorporation into the nanoconjugate lattice, which would reduce intermolecular IR820
aggregation. PEG-mediated steric hindrance may also play a role in preventing
aggregation of IR820 molecules and the subsequent degradation process. The enhanced
preservation of fluorescence properties also indicates that the conjugate is stable as
formulated for at least 72 hours, based on the large differences in fluorescence observed
between conjugate and free dye samples after that time period.

5.2. Cell Imaging Studies

Figure 26 shows fluorescence microscopy images of Dx5, SKOV-3 and MES-SA cell
lines after 4 hours incubation at 5 μM concentration of IR820 and IRPDcov at equivalent
dye content. This concentration was chosen based on our previous cellular studies with
IR820 (Fernandez-Fernandez et al., 2012). In all three cell lines, intense fluorescence was
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observed inside the cells after 4 hour incubation with IR820 or IRPDcov, indicating that
both the free dye and the nanoconjugates were capable of entering the cells. However, the
images taken after IRPDcov incubation showed higher normalized intensity ratios than
those taken after incubation with equivalent concentrations of IR820, especially in Dx5.
Normalized intensity ratios were 1.8 times larger for IRPDcov than for IR820 in Dx5, 1.4
times larger in MES-SA, and 1.2 times larger in SKOV-3.

Figure 26. Cellular imaging of Dx5 (A, B), SKOV-3 (C,D) and MES-SA cells (E,F) after 4 hour incubation
with 5 μM dye content of IRPDcov (top) or IR820 (bottom); 60x, exposure time 4000 ms.

We had previously discussed how PEG can enhance cell membrane interaction and
increase cell internalization by osmoelastic coupling and formation of PEG-induced
fusion vesicles (Yamazaki et al., 1990; Zhang et al., 2002). In the case of IRPDcov, this
may be one of the contributing factors to the enhanced internalization shown by the
fluorescent images, as direct contact with PEG is not necessary to induce such effects. In
comparison to the ionic IR820-PDNCs, IRPDcov produce comparable increases in
internalization for Dx5 (1.7 increase ionic, 1.8 covalent) and MES-SA (1.2 increase ionic,

85

1.4 covalent), and a smaller increase in SKOV-3 (2.1 increase ionic, 1.2 covalent).
Taking into consideration the additional fact that incubation times were 2.5 hours for the
ionic agent versus 4 hours for the covalent formulation, it seems that IRPDcov does not
result in as much enhancement in cellular internalization as the ionic formulation. This is
likely due to the fact that IRPDcov charge is near neutral, which would not facilitate
interaction with the typically negatively-charged cancer cell membranes (Albanese et al.,
2012). Another factor that may account for the difference is that IRPDcov are larger in
diameter than the ionic formulation, and this may cause slower diffusion through the cell
membrane. Ionic IR820-PDNCs are smaller and have a small positive charge, which may
result in increased interaction with negative membranes and larger increases in
internalization based on a combination of size effects, osmotic stress, and charge effects.
However, IRPDcov still show enhanced internalization compared to free dye, most likely
as a result of the PEG-induced osmotic effect. We must also weigh that in vitro behavior
is not the only important parameter to consider. Having a near neutral or zwitterionic
nanoformulation has its own advantages, such as prolonged plasma half-lives and
reduced clearance, which will be important for in vivo applications (Arvizo et al., 2011)
and could render IRPDcov superior to IR820-PDNCs.

5.3. Cytotoxicity and Hyperthermia Studies

We tested IRPDcov to determine whether the dye in nanoconjugate form was still able to
generate heat upon exposure to an 808-nm NIR laser. At a laser fluence rate of 8 W/cm2,
a solution of 0.038 mg/ml IRPDcov (containing 5 μM IR820) caused an increase in
temperature from 37°C to 42.2°C after 3 minutes of exposure, demonstrating that
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covalent binding of IR820 did not interfere with heat generation properties. As previously
discussed, this temperature is in the moderate hyperthermia range (41-43 °C) which can
cause significant tumor cell growth inhibition but does not greatly affect healthy cells.
We also tested PEG-diamine by itself, which did not result in significant changes in
temperature after 3-minute laser exposure compared to wells containing medium only.
Therefore, the IR820 component of the nanoconjugates is responsible for hyperthermia
generation.

SKOV-3, Dx5 and MES-SA cells were chosen to study the cytotoxic effect of IR820 and
IRPDcov on tumor cells with and without hyperthermia. Figure 27 shows net cell growth
following incubation with IR820 or IRPDcov, with or without exposure to laser, for
SKOV-3, Dx5, and MES-SA. All groups were normalized to the control group not
exposed to dye or laser.

Without laser, IRPDcov demonstrates toxicity comparable to the free dye. There was no
significant toxicity in SKOV-3 or Dx5 compared to the control group which was not
exposed to IRPDcov or IR820, and there was a slight growth inhibition in MES-SA cells
for IRPDcov treatment, consistent with our previous observations for IR820. There was
no significant difference in net cell growth between the IR820 group and the IRPDcov
group without laser exposure for any cell line, indicating that IRPDcov can be safely used
up to at least 5 μM. From our previous studies, we determined that laser exposure by
itself or PEG-diamine by itself did not cause any significant effect on cell growth for any
of the three cell lines (Manchanda et al., 2012).
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Figure 27. Cytotoxicity of IRPDcov or IR820 in cancer cell lines, with or without hyperthermia treatment
at 5 μM dye concentration, n = 3 experiments, 4 wells/experiment. All groups are normalized to the control
group not exposed to dye or laser. There was no significant effect of laser exposure per se without IRPDcov
or IR820, and there was no significant effect of PEG-diamine exposed to laser. * = significant difference
(p<0.05) versus non-laser group, **= significant difference (p<0.05) between laser groups.

When exposed to laser, cell growth was significantly inhibited in all three cell lines by
both IR820 and IRPDcov. In MES-SA and Dx5 cell lines, IRPDcov hyperthermia
resulted in significantly higher cytotoxicity (p< 0.05) compared to IR820. In the case of
MES-SA, IRPDcov plus laser resulted in cell killing, versus IR820 plus laser which
caused cell growth inhibition. In SKOV-3 cells, IRPDcov hyperthermia produced higher
cytotoxicity than free dye, but not enough to reach statistical significance. Based on the
cell imaging results displayed in Figure 26, there may be a larger degree of
internalization for IRPDcov than for free dye. This is consistent with the increased
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cytotoxicity effect of the hyperthermia treatment that can be observed in Figure 27.
Enhanced internalization would result in larger accumulation of the dye inside the cell
and an accentuated damaging effect of temperature increases within the cell. This seems
to be most apparent in MES-SA cells, where laser exposure of cells treated with IRPDcov
resulted in a cell killing effect.

When comparing ionic IR820-PDNCs and covalent IRPDcov conjugates, there were no
statistically significant differences in cell growth inhibition between the two
formulations. For both conjugates, the hyperthermia enhanced cytotoxic effect versus free
dye reached statistical significance in MES-SA and Dx5 cell lines, but not in SKOV-3.
This further solidifies the hypothesis that there could an inherent insensitivity to
hyperthermia in SKOV-3, possibly related to the p53 deletion mutation that could affect
apoptotic responses. These results are consistent with similar observations reported by
other researchers who were unable to induce death in SKOV3 cells by treating them with
branched gold nanoparticles exposed to laser at 38 W/cm2 for 5 minutes with an 11°C
temperature increase (Van de Broek et al., 2011), even though the thermal cross section
of gold nanoparticles is higher than that of organic dyes (Yguerabide et al., 1998). It is
apparent that SKOV-3 has inherent thermotolerance. Hyperthermia-induced cytotoxicity
is controlled by both p53-dependent and-independent pathways (Fukami et al., 2004;
Ohnishi et al., 2008; Sturm et al., 2006). Based on existing knowledge, thermosensitivity
and thermotolerance depend on an array of biological, genetic, and environmental factors,
so that a specific cause for SKOV-3 thermotolerance within the context of our studies
cannot be determined.
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As previously discussed in chapter 4, PEG-diamine by itself does not cause oxidative
stress levels able to significantly affect cell growth after laser exposure. However, for
both IR820-PDNCs and IRPDcov, our results showed an enhanced effect of hyperthermia
in Dx5 and MES-SA cells. Increases in cell internalization may play a role in explaining
this difference, but the co-localization of PEG-diamine and IR820 could also have an
effect based on the fact that some mechanisms of cell death in hyperthermia are tied to
oxidative stress responses (Li et al., 2001; Skibba et al., 1997; Wada et al., 2005; Yuki et
al., 2003). IRPDcov nanoconjugates may provide advantages over IR820 alone based on
simultaneous hyperthermia and free radical generation creating a toxic environment for
cancer cells.

5.4. Summary

Under this specific aim, we successfully prepared nanocomplexes of IR820 and PEGdiamine (IRPDcov) and investigated cellular uptake and cytotoxicity in cancer cell lines
MES-SA, SKOV-3 and Dx5. The nanoconjugates were able to generate a cytotoxic
hyperthermia effect, as well as to emit a fluorescence signal that can be used for imaging.
The IPDcov formulation can potentially provide an advantage over the use of free agents
by significantly enhancing the stability of the NIR dye, increasing cell internalization,
allowing simultaneous co-localization of imaging and therapy, and accentuating the
cytotoxic effect of hyperthermia. Additionally, the conjugate nanosize can provide the
advantage of passive targeting by the EPR effect. The next step toward clinical
application is performing animal studies to determine the behavior of the conjugate in
vivo in terms of biodistribution and plasma pharmacokinetics. The expectation is that, due
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to the presence of PEG, the nanoconjugate will have prolonged distribution and
elimination half-lives with respect to the free dye, resulting in advantages for theranostic
applications.
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CHAPTER 6: BIODISTRIBUTION AND PHARMACOKINETIC STUDIES
OF COVALENT IR820-PEG DIAMINE NANOCONJUGATE (IRPDcov), IR820,
AND ICG IN MICE

In vitro studies can provide valuable information, predicting the in vivo behavior of
therapeutic agents by informing us of their physicochemical characteristics in an aqueous
environment and inside cells, however, they cannot reflect the complexity of an actual
living system. Studies using an animal model are the natural follow-up to in vitro studies
of a molecule or agent that shows promise based on in vitro experimental results. In our
case, we proceeded to study the biodistribution and pharmacokinetics of IRPDcov in a
mouse model, and established a comparison with free IR820 as well as ICG in the same
model. The questions we wanted to answer were:

1. Can the IRPDcov conjugate be used for in vivo optical imaging?
2. Is there any difference in biodistribution between IRPDcov, IR820, and ICG?
3. Is there any difference in pharmacokinetic behavior of IRPDcov, IR820, and ICG
in terms of half-life and other pharmacokinetic parameters?

Biodistribution and pharmacokinetics studies are typically done in mice due to their low
cost, ease of handling, and the valuable information they can provide. Mouse models
have been successfully used in many instances of preclinical exploration to determine
pharmacokinetic behavior and safety of drug candidates before they are tested in humans
(European Commission, 2010). There are many examples in the literature of in vivo
testing of optical and therapeutic agents, in their free forms as well as nanoformulations,
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using mouse models. Some examples include studies of the pharmacokinetics of different
formulations of paclitaxel (gel, film, prodrug, liposomes and micelles) in Swiss mice
(Dhanikula et al., 2005); the biodistribution of ICG versus ICG-PLGA nanoparticles in
C57BL/6 mice (Saxena et al., 2006); the biodistribution of ICG versus ICG-containing
electrostatically assembled mesocapsules (MCs) in Swiss Webster mice (Yaseen et al.,
2009); the biodistribution of inorganic luminescent nanoparticles in healthy Swiss mice
as well as tumor-bearing C57BL/6 mice (de Chermont et al., 2007); among countless
others.

Different models can be used in pharmacokinetic analysis to try to approximate the
behavior of a molecular agent in vivo. In the compartmental approach, the researcher
assumes that the drug will be distributed into one or more so called “compartments”,
which represent distinct regions of the body, such as organs or body fluids (Fournier,
2007). In this model, an input function represents drug administration, an output function
represents drug clearance, and mass transfer can occur between compartments at specific
rates (Truskey et al., 2009).

The most straightforward approach to compartmental modeling is to assume the body is a
single compartment. In one compartment models of i.v. bolus administration, the
assumption is that the agent under study distributes uniformly in the body. A drug
injection goes into the “central compartment”, which has a specific volume, and is
eliminated by either inactivation of the agent by metabolism, or excretion in urine and
feces (Truskey et al., 2009).
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A one-compartment model is illustrated in figure 28.

Figure 28. Exemplification of a one-compartment model for pharmacokinetic studies.

Concentration of a molecule over time in one-compartment models can be represented
mathematically by a monoexponential decay equation of the form
C(t)=C0 *e-kt

Equation 4

where C(t) is the concentration as a function of time, C 0 is the modeled initial
concentration, k is the rate constant for clearance, and t is time. The rate constant can be
used to calculate half-life, the amount of time it takes for 50% of the agent to disappear
from the system, as follows:
t1/2 =

ln (2)
k

Equation 5

A more complex approach is the two-compartment model, which takes into account the
fact that molecule transport in plasma is often different from transport in tissue. In a two
compartment model of i.v. bolus administration, the central compartment represents
plasma and well-perfused organs such as the liver, whereas another compartment called
the peripheral compartment represents other organs which uptake the agent (Truskey et
al., 2009). The input injection and the output clearance are still assumed to be happening
to and from the central compartment, but there is also bidirectional mass transfer between
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the central compartment and the peripheral compartment (Fournier, 2007). Figure 29
illustrates the concept of a two-compartment model.

Figure 29. Exemplification of a two-compartment model for pharmacokinetic studies.

In a two-compartment model, pharmacokinetic behavior is biphasic and is characterized
by two distinct phases called distribution and elimination. In the initial distribution phase,
the agent rapidly equilibrates in solution in the central compartment comprised of plasma
and other fluids, and is simultaneously (1) being eliminated from the central compartment
by liver metabolism and kidney excretion, and (2) moving towards or distributing into
the peripheral compartment comprised of other tissues (Bauer, 2008; Truskey et al.,
2009). Although elimination occurs during this phase, the governing process is
distribution. The initial distribution phase corresponds to rapidly declining plasma
concentrations. At the end of this phase, both compartments momentarily equilibrate
reaching steady state, but the concentration gradient is quickly reversed by the fact that
elimination continues to occur in the central compartment, and the second phase starts.
In the subsequent slowly-progressing second phase, the predominant process is
elimination, as the agent is redistributed from the peripheral compartment to the central
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compartment and is eventually cleared from the body (Bauer, 2008; Fournier, 2007).
Concentration vs. time profiles in a two-compartment model can be represented
mathematically by a bi-exponential decay equation of the form:
C(t)=A*e-at +B*e-bt

Equation 6

where C(t) is the concentration as a function of time, A and B are constants whose sum
models the initial concentration, a is the rate constant for distribution, b is the rate
constant for elimination, and t is time (Truskey et al., 2009). From this model, we can
calculate two separate half-lives, one for distribution (initial, rapidly-declining phase) and
one for elimination (slower second phase), based on their corresponding time constants.
The distribution half-life is given by
t1/2 =

ln 2

Equation 7

a

And the elimination half-life is given by
t1/2 =

ln 2

Equation 8

b

For small molecules, higher order compartmental models with a larger number of
compartments may be appropriate to fully understand their behavior in different tissues
(Truskey et al., 2009). In this case, one would follow the same exponential decay models
that were previously described, but with additional terms representing mass transfer
between different compartments.
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As is the case for any model, compartmental models are obviously an oversimplification
of a living system. The choice of a specific compartmental model to represent a set of
data is commonly dictated by expected physiological behavior, the goodness of fit
between data and model, and the degree of improvement in fit when a higher order model
is used. Although a higher order model will often give a better fit, the improvement may
not be significant enough to justify the introduction of complexity into the model, and
there are some inherent dangers in “overfitting” data, such as creating a model that
cannot be generalized (Zuegge et al., 2001). The common approach in the absence of
prior knowledge to guide the researcher seems to be to start with the simplest model
possible, including those reported for agents that could theoretically have a similar
behavior. One can then progress toward increasingly complex models until a satisfactory
fit is achieved.

A way to interpret goodness of fit is to look at the root mean square error (RMSE). Given
the error E as the difference between experimental data and predicted data at a given time
point t, the RMSE is calculated as:
1

RMSE=�n ∑ti=0(Ei )2

Equation 9

The advantage of the RMSE is that it is given in the same units as the original data, so
that it can provide a representation of the size of the average error. As a way to determine
the percent error inherent in our model -and thus in parameters that are computed from
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said model- we can use the root mean square percentage error (RMSPE). To calculate
RMSPE, we calculate the percent error for each prediction and compute RMSPE as:

PE=100*

predicted value-observed value

Equation 10

observed value
1

RMSPE=�n ∑ti=0(PEi )2

Equation 11

Obtaining the value of RMSPE allows us to estimate the percent error that is to be
expected in parameters derived from model equations.

6.1. Study Design
Thirty-six healthy ND4 Swiss-Webster outbred mice, weighing between 25 and 30
grams, were purchased from Harlan (Indianapolis, IN). Animals were housed at the FIU
Animal Care Facility under a 12-hour light/dark cycle and fed ad libitum. All IUCAC
regulations were followed. Table 5 reflects group assignments.

15 minutes

30 minutes

60 minutes

24 hours

IRPDcov

Group 1

Group 4

Group 7

Group 10

IR820

Group 2

Group 5

Group 8

Group 11

ICG

Group 3

Group 6

Group 9

Group 12

Table 5. Study design for biodistribution experiments of IRPDcov, IR820 and ICG in mice. Each group
was comprised of 3 mice.
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Mice were randomly assigned to groups based on optical agent (ICG, IR820, or
IRPDcov), and time point of data collection after injection (15 minutes, 30 minutes, 60
minutes, and 24 hours). Random assignment was performed by card draw, with n=3 for
each group.

6.2. Specific Methodology
6.2.1. Injection and dosage
The literature recommends that a safe i.v. injection volume for mice is 0.2 mL
(Wolfensohn et al., 2003), and other authors have used a 0.24 mg/kg dose of dye for
studies of optical agents in mice (Rajagopalan et al., 2000). Following these guidelines,
animals were weighed and the appropriate solution concentration for this injection
volume based on desired dosage was calculated as follows:

a.

For free dye, we used a 0.24 mg/kg dose, i.e.:
Injection mass=(mouse weight in kg)* �0.24
Solution concentration=

b.

injection mass
0.2 mL

mg
�
kg

For conjugate, we used a 0.24 mg dye/kg dose by adjusting for conjugate dye
content, as follows:
mg

mg dye

Injection mass=(mouse weight in kg)* �0.24 kg � *( mg conjugate )
Solution concentration=
For example: for a 25-g mouse,
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injection mass
0.2 mL

0.025 kg*

0.24 mg IR820
kg

1 mg IRPDcov

* 0.113 mg IR820 = 0.053 mg IR820PDcov

For an injection volume of 0.2 mL,
need solution of

0.053 mg IRPDcov
mg IRPDcov
=0.265
mL
0.2 mL

Solutions for injection were prepared by first dissolving the agents in small volumes of
deionized water, and then diluting in saline solution to the final desired concentration.
Then, 0.2 mL of the solution was placed in a 1-mL syringe with a 30g needle, and the
syringe was covered with aluminum foil to protect it from light. The use of a 30g needle
(instead of the 26g needles utilized in the rat studies) was chosen to accommodate the
smaller diameter and size of the mouse tail veins. Also, because of the small volumes
allowed, no flushing was performed and a direct method of injection was used instead of
the three-way stopcock method we had utilized in rats. Before the injection, an infrared
lamp was used to warm the tail, dilate the veins and facilitate visual localization of the
injection site.

6.2.2. Time sequence of blood and organ sampling
Mice in groups 1-9 were anesthetized with i.p. pentobarbital (100 mg/kg obtained from a
10 mg/mL stock solution), shaved, placed supine on the imaging setup, injected through
the tail vein with their assigned agent, and imaged. At the predetermined time point while
under anesthesia, a blood sample was obtained by heart puncture into the ventricle, and
the animal was then euthanized by removal of the heart. For mice in groups 4-9, the
pentobarbital dose was given in two injections, the first 50 mg/kg before imaging, and the
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second 50 mg/kg administered 15 minutes before the terminal time point. The dose was
split in this manner, rather than given in a single dose, in order to ensure survival until the
terminal time point. For mice in groups 10-12, each animal was anesthetized with 40
mg/kg of i.p. pentobarbital, injected with the assigned agent, and imaged. These mice
were then returned to their cage alive until the 24-hour time point. After 24 hours, they
were anesthetized with 100 mg/kg of i.p. pentobarbital and imaged again under the same
operating conditions. After imaging, a blood sample was obtained by heart puncture, and
organs were carefully harvested for imaging and subsequent homogenization and dye
extraction. These animals were finally euthanized by removal of the heart.

6.2.3. In vivo imaging techniques
The same general techniques for animal and organ imaging that were described in chapter
2 were followed for the mice studies, including the setup used and the software for
processing the data.

6.2.4. Plasma and organ sample processing
Plasma and organ sample processing followed the procedures described by other
researchers who have performed biodistribution studies of NIR dyes and related
compounds (Saxena et al., 2006; Yaseen et al., 2009). In the case of blood samples,
immediately after collection the samples were centrifuged 2x for 3 minutes at 12,000 rpm
to extract plasma. Plasma samples were then incubated in DMSO (1 plasma: 50 DMSO)
in glass vials covered with aluminum foil for thirty minutes and centrifuged again. The
resulting supernatant was used to perform spectrofluorometric measurements of dye

103

concentration in plasma using a previously created calibration curve of IR820 or ICG in
DMSO at 785-nm excitation.

For organ samples in the 24-hour groups, organs were carefully dissected and placed in
black-coated Petri dishes for imaging as previously described for our rat studies.
Fluorescent organs were then cut into small pieces using a scalpel, placed in pre-weighed
glass vials, and homogenized using a tissue homogenizer. The vials with homogenized
samples were reweighed, and 5 mL of DMSO was added for dye extraction. Samples
were incubated in DMSO for 4 hours covered with aluminum foil, and centrifuged at
9,000 rpm for 15 minutes. The supernatant was used to perform spectrofluorometric
measurements of dye content using a previously created calibration curve of IR820 or
ICG in DMSO at 785-nm excitation. To report the data, organ dye content was
normalized to organ mass.

6.2.5. Pharmacokinetic analysis of plasma data
Dye concentration in plasma obtained from spectrofluorometer measurements was
averaged for each group, and the average concentration for each time point was entered
into Matlab (MathWorks, Natick, MA). The initial concentration (concentration at
injection) was estimated for an average 25-g mouse. The injected amount was
approximately 6 µg dye based on the 0.24 mg/kg standardized dosage, with a mouse
plasma volume of approximately 1.5 mL based on literature ratios of 58.5 mL plasma /kg
body weight (Macon et al., 2011). This results in an initial concentration of
approximately 4 µg dye/mL in plasma.
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Using the curvefit tool in Matlab, average data points at 0, 15, 30, 60 minutes, and 24
hours were fit to both monoexponential and biexponential curves via a least squares
algorithm. As discussed before, researchers attempting to model pharmacokinetic
behavior often choose to start with the simplest model that is theoretically sound for a
given set of experimental data, and progress to more complicated models as needed based
on fit results. In our case, literature shows that ICG pharmacokinetics have been modeled
by other authors with either a one-compartment or a two-compartment model approach
(Achilefu et al., 2002). Given these sources, there is justification to attempt to fit the data
for ICG, IR820, and IRPDcov to monoexponential and biexponential curves as an initial
approach. We do not truly know if these will be appropriate for IR820 and IRPDcov,
because nothing has been reported in the literature regarding IR820 pharmacokinetics,
and IRPDcov is a novel conjugate. Regardless, it seems wise to start our modeling efforts
by utilizing what has been reported by others for ICG. We would expect the behavior of
these agents to be somewhat similar to ICG, especially in the case of IR820. Thus, we
focused on one-compartment and two-compartment pharmacokinetic models. The
resulting monoexponential and biexponential fit equations were used to determine the
overall half-life (in the case of the monoexponential model), or the half-lives of
distribution and elimination (in the case of the biexponential model). Other calculated
pharmacokinetic values included the area under the pharmacokinetic curve, the mean
plasma residence time, and the clearance rate.

The area under the curve (AUC) is the integral of the concentration vs. time curve, which
we calculated using Simpson’s rule.
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∞

Area under the curve= AUC= ∫0 C(t)dt

Equation 12

The mean residence time in plasma, t p , is the average time spent by the agent of interest
in plasma, and is given in its simplest expression by:

Mean plasma residence time=tp =

AUC
C0

Equation 13

where C 0 is the modeled original concentration. This value corresponds to the coefficient
C 0 in a monoexponential model, and to the sum of coefficients A+B in a biexponential
model.

The total body clearance rate (i.e. volume of agent cleared from the body per unit time) is
given by:
Dose

Total body clearance rate= AUC

Equation 14

Based on the preceding calculations, we compared IRPDcov, IR820 and ICG
pharmacokinetic parameters using one-way ANOVA (p<0.05) followed by Bonferroni
post-hoc test.

6.3. Results and Discussion
6.3.1. Animal imaging
Figure 30 shows representative images obtained from ICG, IR820, and IRPDcov animals
15 minutes and 24 hours after injection.
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Figure 30. Images taken 15 minutes and 24 hours after i.v. injection for IRPDcov, IR820, and ICG.

These images prove that IRPDcov can be used for in vivo imaging and that it provides an
imaging signal comparable to that of IR820. As expected based on our prior rat imaging
experiments, the signal ratio for ICG at 15 minutes after injection was higher than that of
IR820 or IRPDcov. However, in agreement with our previous data, by 24 hours the
intensity of ICG had dropped significantly in comparison with the other two agents. The
24-hour ICG signal also seemed to be located in the lower abdomen, instead of in the
liver region as is the case for the other two agents.

6.3.2. Organ imaging
Organ images obtained after 24 hours demonstrate a very different biodistribution for
ICG compared to the other two agents. Figure 31 provides a qualitative comparison of
organ signals for IRPDcov, IR820, and ICG, and Table 6 summarizes the organ signal
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intensity per unit area ratios for each dye. The information obtained from the ratio data
indicates that the biodistribution of IRPDcov, IR820, and ICG shows a different pattern
between agents 24 hours after i.v. injection.

Image intensity per area, R (1/µm2)
IRPDcov

IR820

ICG

6.35±0.44*(p<0.001)

6.13±1.44* (p=0.002)

0.76±0.35

0.64±0.08*(p=0.04)

2.48±0.47* (p=0.001)

0.18±0.32

Kidneys

1.34±0.13*(p=0.003)

2.95±1.88*(p=0.04)

0.20±0.34

Intestines

0.65±0.10

1.00±0.45

2.01±1.43

Liver
Lungs

**(p=0.003)

Table 6. Signal intensity ratios for liver, lungs, kidneys and intestines collected 24 hours after i.v. injection
of IRPDcov, IR820, or ICG. Values represent average±SD. * = Significant difference (p<0.05) with ICG
values for the same organ; ** = Significant difference (p<0.05) between IRPDcov and IR820 values for the
same organ.

Although an ICG signal was still present in the liver, the ratio was significantly lower
(p<0.05) than for IR820 or IRPDcov. The amount of ICG present in the kidneys and the
lungs was also significantly smaller (p<0.05) than for the other two agents. In the case of
the intestines, a higher signal was observed for ICG than for IR820 or IRPDcov,
however, the effect did not reach statistical significance due to large standard deviation
for ICG measurements in the intestines.

We expect that inter-subject variability in

intestinal motility rates would affect ICG more markedly, given that most of the dye is
being eliminated via the gastrointestinal tract at the 24-hour time point.
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Figure 31. Organ images taken 24 hours after i.v. injection of IRPDcov, IR820, or ICG.

In the case of IR820, a strong signal was observed in the liver, kidneys, and lungs, with a
small signal in the intestines. IRPDcov showed a strong signal in the liver, some signal in
the kidneys, and a small signal in lungs and intestines. Statistical analysis comparing
IR820 and IRPDcov showed that there were no differences in liver or intestinal image
ratios. There was a significant difference (p<0.05) in lung image ratios, with IRPDcov
showing a smaller signal ratio than IR820. This possibly indicates that the
nanoformulation was able to escape detection by alveolar macrophages thanks to the
presence of PEG, which reduces binding to serum proteins (Li et al., 2008). In the
kidneys, the IRPDcov signal was smaller than that of IR820, but the difference did not
reach statistical significance. There may be a somewhat smaller degree of elimination of
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IRPDcov through the kidneys, which would be consistent with the expectation that the
larger size of the conjugate compared with the free dye would result in decreased renal
clearance based on a low molecular size cutoff for renal excretion (Li et al., 2008), as
well as the fact that the presence of PEG could result in reduced reticuloendothelial
system uptake. However, the small number of subjects in our study may not provide
enough sensitivity to detect a significant difference. Another reason for the lack of
significance could be variability in renal elimination rates between subjects. Additionally,
imaging ratios may not be sensitive enough to detect quantitative differences.

From these images we can conclude that there are clear differences in the biodistribution
patterns of ICG versus IRPDcov and IR820, with ICG being more rapidly cleared from
major organs than the other two agents, and primarily localizing in fecal elimination
pathways by 24 hours. In terms of comparing IRPDcov with IR820, our lung images
support the hypothesis of reduced mononuclear phagocyte system uptake (Li et al.,
2008), which we can probably owe to the presence of PEG. Additionally, it is possible
that further studies with larger numbers of subjects could also detect reduced localization
to the kidneys.

6.3.3. Organ dye content
Table 7 shows the average dye content in µg dye/g tissue for liver, lungs, kidneys and
intestines 24 hours after an i.v. injection of IRPDcov, IR820, or ICG. The data is
consistent with our qualitative observations and quantitative signal ratios from the optical
imaging samples, and provides increased sensitivity to detect differences.
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Organ dye content (µg dye/g tissue)
IRPDcov

IR820

ICG

Liver

0.25 (4.1%)±0.03*

0.21(3.6%)±0.11*

0.01(0.6%)±0.003

Lungs**

0.12(2.0%)±0.02*

0.28(4.7%)±0.03*

0 - Background signal

Kidneys

0.31(5.2%)±0.10*

0.42(6.9%)±0.11* 0 - Background signal

Intestines

0.03(0.5%)±0.01*

0.05(0.8%)±0.01*

0.07(1.2%)±0.02

Table 7. Quantitative organ content 24 hours after after i.v. injection of IRPDcov, IR820, or ICG.
Values represent average±SD(%ID). * = Significant difference (p<0.05) with ICG values for the same
organ; ** = Significant difference (p<0.05) between IRPDcov and IR820 values for the same organ

When we compare the results for ICG with those of IRPDcov and IR820, we see that
organ content was significantly higher in the intestines, and significantly lower in all
other organs. For lung and kidneys, ICG sample readings were at background level.
When comparing IRPDcov and IR820, the only significant difference was a reduced
content of IRPDcov in the lungs. IRPDcov kidney content was lower than for IR820, but
the difference was not significant. Thus, the interpretation presented in section 6.3.2. is
supported by our quantitative analysis of organ dye content. Additionally, the difference
between intestinal uptake of ICG, IRPDcov, and IR820 becomes significant once
quantitative organ dye content was used as a measurement.

6.3.4. Plasma dye concentration
Table 8 shows the average dye concentration in plasma in µg/mL for IRPDcov, IR820,
and ICG at each of the time points under study. We observed significantly higher
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(p<0.05) plasma concentrations of IR820 and IRPDcov compared to ICG for all time
points, with plasma values 20 times higher at 24 hours for IRPDcov, and 10 times higher
for IR820. We also found significantly higher (p<0.05) concentrations of IRPDcov
compared to IR820 at the 30-minute, 60-minute, and 24-hour time points, with plasma
concentration of IRPDcov double that of IR820 at the 24-hour sampling time.

Dye
Time

IRPDcov

IR820

ICG

15 minutes

2.52±0.99*(p=0.008)

1.94±1.17*(p=0.03)

0.20±0.16

30 minutes **(p=0.01)

1.80±0.29*(p<0.001)

0.97±0.15*(p<0.001) 0.07±0.004

60 minutes **(p<0.001) 0.83±0.03*(p<0.001)

0.34±0.03*(p<0.001) 0.05±0.02

24 hours **(p<0.001)

0.10±0.01*(p<0.001) 0.01±0.003

0.20±0.02*(p<0.001)

Table 8. Plasma concentrations (µg/mL) of IRPDcov, IR820, and ICG at different time points after i.v.
injection. Values represent average±SD. * = significant difference from ICG, p<0.05; ** = significant
difference between IRPDcov and IR820, p<0.05.

Based on these results, not only were IR820 formulations superior to ICG as expected in
terms of plasma concentration over time, but we also observed a clear advantage of the
IRPDcov conjugate over IR820 after initial distribution. This confirms the applicability
of the theoretical foundation that justified the formulation of this conjugate, which relied
on the possibility that the presence of PEG could contribute to improved plasma
concentration profiles by reducing detection by macrophages and other circulating agents
in plasma. IRPDcov is thus analogous to other formulations where the inclusion of PEG
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has provided some stealth characteristics in an in vivo environment. The differences
observed between IR820 and IRPDcov are most likely due to differences in charge, size,
and surface characteristics, which are discussed in section 6.2.5.

The recovered percent injected dose at 24 hours in plasma was 3.3% for IRPDcov, 1.7%
for IR820, and 0.8% for ICG. If we add these numbers to the percent values of the
recovered injected doses found in our organ content studies, we reach an overall percent
of 15.1% for IRPDcov, 17.7% for IR820, and 2.6% for ICG.

In the case of ICG, almost the entire injected dose has been lost after 24 hours, which
demonstrates a clear advantage of the IR820 formulations in terms of injected dose
recovery at this time point. Surprisingly, we did not observe a larger percent dose
recovery for IRPDcov compared to IR820. A possible explanation may be that, as the
circulating concentration of IRPDcov is still double that of IR820 at 24 hours, it is
possible that a considerable amount of the conjugate may yet be present in other nonsampled tissues, such as fat, skin, muscle, bone, or the lymphatic system.

6.3.5. Pharmacokinetic modeling
Figure 32 below shows a representative screenshot of the Matlab curvefit tool. All dyes
were fit to both a monoexponential and a biexponential model, and goodness of fit was
assessed by R2, RMSE, and calculated RMSPE. The latter two were calculated as
previously described by comparing model predictions with experimental data.
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Figure 32. Sample curve fit for plasma concentration data using the curvefit tool in Matlab

Figure 33 shows the plasma pharmacokinetic profiles for IRPDcov, IR820, and ICG, in a
graph created using Sigmaplot (Systat Software, San Jose, CA).

Figure 33. Pharmacokinetics of IRPDcov, IR820, and ICG plasma concentrations vs. time after i.v. dose.

a. One-compartment modeling
Table 9 shows the resulting parameters from a one-compartment modeling approach to
IRPDcov, IR820, and ICG data, given the monoexponential equation:
C(t)=C0 *e-kt
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Model equation
R2
RMSE
RMPSE
Half-life (hours)
AUC [µg-h/mL)]
Mean plasma
residence time, t p (h)
Total body clearance
rate (ml/h)

IRPDcov
C(t)=3.952*e-1.619t
0.9912
0.1396
2.40%
0.428±0.010 †, ††
2.441±0.059†, ††
0.610±0.015†, ††

IR820
C(t)=3.984*e-2.805t
0.9971
0.0848
2.00%
0.247±0.005†, ††
1.420±0.028†, ††
0.355±0.007†, ††

ICG
C(t)=4*e-11.87t
0.999
0.0434
1.94%
0.058±0.001
0.340±0.007
0.085±0.002

2.46±0.06†, ††

4.22±0.08†, ††

17.6±0.34

Table 9. Pharmacokinetic parameters from one-compartment analysis of dye data in mice. † = significant
difference (p<0.05) with ICG; †† = significant difference (p<0.05) between IRPDcov and IR820.

The monoexponential model provided a good fit to our data, with R2 values over 0.99 for
all dyes, and percent errors under 2.5%. According to this model, both IR820 and
IRPDcov demonstrate significantly longer half-lives, larger AUC, longer t p , and slower
body clearance rates than ICG. All of these are signs of prolonged blood circulation (Li et
al., 2008). Additionally, IRPDcov also showed a significant advantage over IR820 for all
of these parameters, indicating that the nanoformulation resides longer in plasma and is
eliminated from the body more slowly. However, it seems that the calculated clearance
rates represent quite large volumes for a mouse, which leads us to question the
physiological validity of the model.

b. Two-compartment modeling
Table 10 shows the resulting parameters from a two-compartment modeling approach to
IRPDcov, IR820, and ICG data, given the biexponential equation:
C(t)=A*e-at +B*e-bt
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Model equation
based on plasma data
R2
RMSE
RMPSE
Distribution half-life
(h)
Elimination half-life
(h)
AUC [µg-h/mL)]
Mean residence time
in plasma (h)
Total body clearance
rate (ml/h)

IRPDcov
C(t)=3.666*e-1.905t
+0.3162*e-0.01955t
0.9953
0.1023
1.59%
0.364±0.006†, ††

IR820
C(t)=3.831*e-3.108t
+0.1702*e-0.02275t
0.9999
0.0120
1.49%
0.223±0.003†, ††

ICG
C(t)=3.927*e-13.54t
+0.0734*e-0.3752t
0.9999
0.0094
1.51%
0.051±0.001

35.46±0.56†, ††

30.45±0.45†, ††

1.85±0.03

7.98±0.13†, ††
1.99±0.03†, ††

4.38±0.07†, ††
1.09±0.02†, ††

0.490±0.007
0.12±0.002

0.75±0.01†, ††

1.37±0.02†, ††

12.25±0.18

Table 10. Pharmacokinetic parameters from two-compartment analysis of dye data in mice. † = significant
difference (p<0.05) with ICG; †† = significant difference (p<0.05) between IRPDcov and IR820.

As can be seen in Table 10, the biexponential model modestly improved the fit for
IRPDcov in terms of R2 values compared to the monoexponential model, and did not
improve the fit for IR820 and ICG, which was expected because the value of R2 was
already very good for both dyes in the monoexponential model. The percent errors
inherent in the biexponential model are all 1.6% and lower, which is a reduction from the
monoexponential model. Total body clearance rates seem more physiologically plausible.

Based on this, it seems that the biexponential model may provide a better understanding
of our data. It can also provide us with separate insight into the distribution and
elimination behavior of each agent, and allow further comparisons between formulations.
According to this model, both IR820 and IRPDcov demonstrate significantly longer
(p<0.05) distribution half-lives, longer elimination half-lives, larger AUC, longer plasma

116

residence times, and slower body clearance rates than ICG. Although distribution
happens quite fast for all agents, ICG distribution half-life is approximately 3.06 minutes,
whereas the value for IR820 is 13.4 minutes, and for IRPDcov 21.8 minutes. The value of
distribution half-life for ICG is consistent with that previously reported by other authors,
which ranges from 2 to 4 minutes (Desmettre et al., 2000; Mordon et al., 1998). The
calculated elimination half-lives for IRPDcov and IR820, which both exceed 30 hours, is
in stark contrast with that of ICG, which is 1.85 hours. These values are also well aligned
with some of the conclusions reached by Prajapati’s group, who determined that IR820
binds to albumin and should have a clearance half-life close to that of albumin, which is
in the order of 35 hours (Prajapati et al., 2009). The elimination half-life value we
obtained for ICG is consistent with literature data, as other authors report an elimination
half-life of over 1 hour at low concentrations (Desmettre et al., 2000).

Both the distribution and the elimination phases show improved profiles for IR820
formulations compared to ICG in terms of providing a wider time window for theranostic
action. As far as the area under the concentration-time curve, both IRPDcov and IR820
are an order of magnitude larger than ICG, indicating an increased overall exposure to the
theranostic agent. Additionally, IRPDcov also shows a significant advantage (p<0.05)
over IR820 for all the above calculated parameters, with almost double the AUC and the
mean plasma resident time of IR820, and almost half the clearance rate of IR820. The
nanoformulation is present in plasma for longer periods of time, eliminated more slowly
from the body, and the cumulative exposure of body compartments to the conjugate is
larger than for any of the two free dyes. The time that the IRPDcov is bioavailable is also
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significantly longer, as the elimination half-life of IRPDcov is 1.16 times longer than that
of IR820, and 19 times longer than that of ICG; whereas the distribution half-life of
IRPDcov is 1.6 times longer than that of IR820, and 7 times longer than that of ICG.

Given that the enhanced permeability and retention effect is proportional to the time and
amount of agent circulating in blood (Saxena et al., 2006), we would theoretically expect
IRPDcov to result in a greater amount of dye accumulated and retained in tumors.
However, further studies in a tumor-bearing model would be needed to explore this
possibility.

Other authors have studied the pharmacokinetics of nanoformulations and the general
consensus is that nanoformulations may result in improved pharmacokinetic profiles, in
many cases as a result of stabilization of the drug and reduced liver metabolism and renal
clearance (Li et al., 2008). Still, loss of nanocomplexes from the circulation can occur by
binding to serum proteins in the process known as surface opsonization, which
subsequently causes recognition and removal by circulating phagocytes or macrophages
(Albanese et al., 2012; Moghimi et al., 2012). In the case of PEGylated formulations,
steric hindrance reduces the degree of protein binding, resulting in prolonged circulation
times and giving PEGylated formulations an improved pharmacokinetic profile compared
to their non-PEGylated counterparts (Albanese et al., 2012; Li et al., 2008). This seems to
be applicable to formulations incorporating PEG as a conjugated moiety as is the case of
the IRPDcov conjugate.
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Another consideration which is intimately tied to these profiles is the surface charge of
the formulation. Our nanoconjugates are zwitterionic, presenting both positive and
negative charges and with an overall zeta potential that approaches neutrality. Other
authors have found that, for other physical characteristics being similar, neutral and
zwitterionic nanoformulations exhibit prolonged plasma half-lives and reduced clearance
compared to largely positive or largely negative formulations, which indicates that charge
may play a large role in maximizing circulation time (Arvizo et al., 2011).

Nanocomplex size also has an effect on circulation time, with particles around 100 nm
diameter demonstrating longer blood circulation profiles than larger or smaller particle
sizes (Li et al., 2008). Liu et al studied the effect of size on biodistribution of liposomes,
and found that sizes between 100 and 200 nm were present in circulation for longer times
than those greater than 250 nm or smaller than 50 nm (Liu et al., 1992). Given that our
nanoconjugates are around 150 nm per SEM measurement, it seems that size is also
contributing to their prolonged circulation times.

6.3.6. Limitations
Our analysis is not without possible limitations. First, the pharmacokinetic models we
have used have important assumptions such as uniform distribution, no absorption, rapid
equilibration before sampling, and no degradation. Uniform distribution may be an issue,
as we know that nanoformulations are distributed to tissues depending on pore size, in a
different manner than their free form counterparts (Cho et al., 2008; Dhanikula et al.,
2005; Li et al., 2008). Regarding absorption, both the monoexponential and biexponential
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models were good fits for our data and they both ignore absorption, thus we are quite
confident that absorption is negligible enough to not impact our interpretation of the data.
In terms of rapid equilibration, others have reported that equilibration of injected
solutions in mice plasma can be assumed to happen within 2 minutes (Berezhkovskiy,
2009). Since our first sample was taken at 15 minutes, we can assume that equilibration
has occurred by that time, and we do not expect this assumption to be broken. Regarding
the possibility of degradation into other byproducts, other authors have shown that ICG is
mostly excreted in its intact form in bile (Achilefu et al., 2000; Saxena et al., 2006). Our
in vitro studies show that IRPDcov conjugates are very stable and retain their
characteristics for at least 72 hours in phosphate buffered saline. Based on this, we do not
expect degradation to be a significant concern within the time periods studied in vivo.
However, the in vivo environment cannot be fully mimicked by in vitro conditions, and
some in vivo factors such as the presence of plasma proteins, reticuloendothelial system
scavengers, and metabolism in liver or other tissues may result in aggregation,
degradation, or changes in the structure of these molecules.

A final consideration in terms of calculated pharmacokinetic parameters is the recent
discussion regarding classical estimates of plasma residence time versus newer estimates
that adjust for drug or agent elimination during the initial distribution period.
Berezhvosky has proposed a revised plasma residence time equation that takes into
consideration the time that it takes to reach a uniform plasma distribution
(Berezhkovskiy, 2009). When we repeated our calculations using his equation, the values
of plasma residence time for IRPDcov, IR820, and ICG were all within 0.02 hours of the
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values we calculated using classical equations. Thus, although the revised equation may
be useful for agents that have initial extremely rapid elimination profiles, we are
confident that this is not a significant issue in the case of IRPDcov, IR820, or ICG, and
we have chosen to report the classically calculated values of plasma residence time as a
function of AUC and initial estimate of concentration. Moreover, the fact that our values
barely changed using either of the two calculation approaches also provides some
confidence that our assumed initial concentration in plasma is likely to be reasonably
accurate.

There are other concerns besides those arising from the models we used to approximate
the in vivo pharmacokinetics of these agents. An important one may be the fact that we
used parallel sampling, in which each data point is an isolated animal, rather than serial
sampling, where samples are taken from the same animal over time. Although serial
sampling has the advantage of reducing inter-subject variability in the concentration vs.
time curves, it also puts the subjects at risk due to repeated blood sampling based on the
procedure itself as well as the cumulative amount of blood lost that could lead to
hypovolemic shock (Wolfensohn et al., 2003). Blood collection by heart puncture is best
considered a terminal collection method (Hoff, 2000), and the alternative which is
typically tail blood collection may not give us correct information as there is the potential
for residual dye contamination of the tail. The fact that we achieved good model fits
using parallel sampling seems to indicate that no large inter-subject variations were
introduced by the method we used.
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Another concern is the inability to flush the tail due to injection volume limitations. Other
authors have reported that a large amount of sample can be left in the tail vein (Yaseen et
al., 2009), which complicates the interpretation of the pharmacokinetic analysis by
assuming an initial concentration in plasma that is not an accurate representation of the
percentage dose that reached the central compartment. Goodness of the model fit seems
to provide reassurance that this was not a significant concern in our studies.

Additionally, when considering our organ localization analysis based on imaging and
quantitative content data, the applicability of our conclusions is limited by the fact that
we only collected organs at the 24-hour data point. However, based on the results
showing that IR820 and IRPDcov have much slower distribution and elimination profiles
than ICG, we would not expect that additional data collected in the range of one hour
after injection would reveal any further information than that provided to us by the 24hour time point. This time point allows us to clearly highlight the differences between
agents, and provides us with information within a clinically relevant theranostic window.
The same could be said for our plasma data and the selection of four time points in terms
of whether there are sufficiently representative. Although of course obtaining as many
samples for as many time points as possible is always desirable, one of the central tenets
of science is the ability to prioritize while designing an experiment. Our goal should be to
design an experiment that allows us to obtain the most relevant pieces of information, i.e.,
those which will help us answer our starting questions. We are confident that the data we
have collected provides a good insight into the behavior of these agents in an in vivo
model.
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6.4. Summary
Biodistribution and pharmacokinetic studies of IRPDcov, IR820, and ICG in mice show
that IRPDcov is a feasible alternative to IR820 for in vivo imaging, and that it
demonstrates an improved pharmacokinetic profile over the free dye form as well as over
the commonly used near-infrared dye ICG. The IRPDcov conjugate has different organ
localization than free IR820, with potential reduced accumulation in the kidneys and
significantly lower (p<0.05) accumulation in the lungs. Both IRPDcov and IR820 had
entered fecal elimination pathways to a lesser extent than ICG after 24 hours, with larger
overall recovered percent injected dose from major organs and plasma compared to ICG.
Plasma IRPDcov concentration was significantly higher than that of IR820 for time
points after the initial 15 minutes post-injection, and both IR820 formulations (conjugate
and free form) showed higher plasma concentrations than ICG at all sampling points after
injection. When plasma concentration was modeled using a two-compartment approach,
the conjugate demonstrated a biphasic profile with significantly longer distribution and
elimination half-lives, longer mean plasma residence time, larger overall exposure as
indicated by AUC, and slower clearance rate compared to either IR820 or ICG. The
nanosize nature of our conjugate, as well as surface and charge characteristics provided
by the presence of PEG, is likely to be responsible for these differences. The use of
IRPDcov conjugates could provide wider dye in vivo availability windows for theranostic
applications.
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CHAPTER 7: OVERALL DISCUSSION AND CONCLUSIONS

The development of multifunctional agents for cancer management is a rapidly growing
field which can result in improved diagnosis and therapy for patients with cancer. Recent
developments in nanotechnology have fueled the growth of theranostics research,
because nanoformulations have unique characteristics that make them well-suited to
customized therapy approaches and multimodal applications. Nanosize therapeutic and
diagnostic agents can be tailored to a specific application by manipulating their size,
shape, surface characteristics, and other physiochemical properties, resulting in
personalized strategies to treat disease. This frame of thought involves the customization
of diagnostic and therapeutic approaches to a specific disease process, and is especially
relevant in disorders such as cancer, which is very heterogeneous and encompasses a
large spectrum of alterations in cellular processes and behavior. Customizable medicine,
along with the combination of diagnostic and therapeutic approaches to improve
management such as the ability to use imaging to guide therapy, opens the door to a new
era in patient care.

Near-infrared dyes can be used as theranostic agents in cancer management based on
their optical imaging and localized hyperthermia capabilities, however, they have
important limitations which limit their applicability for theranostic use, especially in
terms of photobleaching, in vivo instability and non-specific biodistribution (Frangioni,
2003). Another concern based on these disadvantages is the ability to provide convenient
timing for combined imaging and therapy. In our work, we studied the properties of the
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cyanine dye IR820, and provided the first detailed report of its potential for use in
theranostics. We studied the applications of IR820 in optical imaging and hyperthermia,
and we prepared nanoconjugate formulations that retain or improve upon these
theranostic capabilities.

We chose to study the cyanine dye IR820 because of its chemical structure. IR820 is
structurally similar to indocyanine green (ICG), which is a clinically approved cyanine
dye. ICG can be used in imaging and hyperthermia applications, so we expected IR820 to
have similar multi-functionality. On the other hand, we hypothesized that the presence of
a chlorohexene ring in IR820 which is absent in ICG could mean that IR820 would have
improved stability as well as more amenability to conjugation. Our results showed that
IR820 has optical and thermal generation properties similar to indocyanine green, but
with improved in vitro and in vivo stability. The fluorescent emission of IR820 has a
lower quantum yield than ICG, but less dependence of the emission peak location on
concentration. This predictability of peak location for IR-820 could facilitate the design
of imaging systems targeting IR-820 emission wavelengths. Additionally, IR820
demonstrated higher stability than ICG in aqueous solution under all temperature and
light conditions, with degradation half-times approximately double those of ICG for a
given experimental condition. IR820 is still susceptible to photobleaching, but less so
than ICG. In hyperthermia applications, IR820 generated lower peak temperatures than
ICG (4-9%) after three-minute laser exposure. However, it was still able to cause
temperature increases into the desired hyperthermia range of 40-43°C that is able to
selectively impact tumor cell growth. There was no significant difference in hyperthermia
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cytotoxicity between IR820 and ICG, with both dyes causing cancer cell growth
inhibition at 5 µM and cell killing at 10 µM upon laser exposure. Free IR820 can be used
for in vitro and in vivo optical imaging, with a strong detectable signal still present in rats
24 hours after i.v. injection, a plasma half-life in the order of hours, and primary
biodistribution to the liver, lung, and kidneys. Our study shows that IR820 is a feasible
agent in experimental models of imaging and hyperthermia, and could be an alternative to
ICG when greater stability, longer image collection times, or more predictable peak
locations are desirable.

Even though IR820 is a promising theranostic agent, clinical translation of NIR-imaging
and hyperthermia approaches in cancer must overcome the challenges presented by free
dye formulations in terms of plasma circulation times and non-specific biodistribution.
Nanotechnology provides some opportunities to improve in vivo stability and target
delivery. Physicochemical characteristics of nanoformulations such as size, surface
charge, and surface characteristics can be modified to alter their interactions with
circulating immune system components and with cellular membranes. In terms of the
behavior of nanoformulations in vivo, it has been shown that nanosize agents are less
susceptible to reticuloendothelial system clearance and have better penetration into
tissues and cells than larger size agents (Brigger et al., 2002; Xu et al., 2006).
Nanoformulations can also take advantage of the enhanced permeability and retention
(EPR) effect thanks to their size, and thus are inherently able to accumulate preferentially
at tumor sites through passive targeting (Iyer et al., 2006).
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We chose to conjugate IR820 with polyethylene glycol (PEG) to create a
nanoformulation with additional desirable properties in terms of in vivo behavior, besides
the advantages imparted by its nano nature. Research has shown that the presence of PEG
in nanoformulations can reduce capture by the immune system, and result in improved
plasma circulation times (Harris et al., 2001). Longer exposure to the theranostic agent
provides a wider window of opportunity for diagnosis and therapy, and allows more
flexibility in terms of timing, one with respect to the other, as needed for a specific
application. Additionally, PEG can be used as a linker to conjugate other moieties and
impart new functionality such as specific targeting.

The first step in exploring the potential of an IR820/PEG nanoconjugate for theranostic
applications was to create ionic conjugates and determine if the optical and thermal
generation properties of IR280 were preserved as part of a conjugate lattice. We
successfully prepared ionic IR820-PEG-diamine nanoconjugates (IRP820-DNCs) which
were approximately 50 nm diameter in SEM images, and had a zeta potential of 2.0±0.9
mV. IRPDNCs showed enhanced cellular internalization in SKOV-3, MES-SA, and Dx5
cells for imaging purposes compared to the free dye, possibly due to osmotic stress on
cellular membranes induced by the proximity of PEG. Cytotoxicity studies in SKOV-3,
MES-SA and Dx5 cancer cell lines showed comparable cytotoxicity of IR820-PDNCs
versus free IR820 after 24 hours. IR820-PDNCs were able to produce hyperthermic cell
growth inhibition in all three cancer cell lines after excitation with laser, and they
significantly enhanced hyperthermia-mediated cytotoxicity in MES-SA and Dx5
compared to hyperthermia using free dye. We concluded that this formulation can
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potentially provide an advantage over the use of free agents by enhancing cell uptake,
allowing simultaneous co-localization of imaging and therapy, and accentuating the
cytotoxic effect of hyperthermia.

After proving that IR820 retained its ability to generate heat and fluoresce when
interacting in close proximity with PEG as part of an ionic formulation, we hypothesized
that modifying this formulation to create covalent conjugates could improve on the
stability of the lattice and result in nanosize conjugates that may be used in in vivo
applications with improved pharmacokinetic profiles compared to the free dye. Thus, we
prepared and characterized covalent conjugates of IR820 and PEG-diamine (IRPDcov).
IRPDcov retained the ability to fluoresce after 785-nm excitation and to be used for in
vitro optical imaging of cancer cells as well as in vivo imaging. In vitro cellular
internalization was not as large as for ionic conjugates, but it was still larger than for free
dye. IRPDcov also retained the heat-generation ability of IR820 upon exposure to 808nm laser, and was significantly more stable than IR820 in aqueous solution over a period
of 72 hours. In mouse plasma samples, IRPDcov and IR820 when compared to ICG
demonstrated significantly longer (p<0.05) distribution half-lives, elimination half-lives,
and area-under-the-curve values. For IRPDcov, the area under the kinetic curve was
almost 16 times larger than that of ICG, and approximately double that of IR820,
indicating significantly longer overall exposure to the probe. This could pose an
advantage in therapeutic probe applications such as hyperthermia or drug delivery.
Regarding organ biodistribution, both IR820 and IRPD showed a very strong signal in the
liver and lower-intensity signal in the kidneys 24 hours after i.v. injection, whereas the
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predominant signal for ICG was weak and located in the intestines, demonstrating a much
more rapid GI elimination. IRPDcov was different from IR820 in that the latter showed a
signal in the lungs, which was not present in IRPDcov subjects. This indicates that
IRPDcov may have been able to escape detection by alveolar macrophages. Our results
are consistent with existing literature reports of increased half-life and decreased immune
system uptake for PEGylated nanoformulations (Albanese et al., 2012; Arvizo et al.,
2011; Brigger et al., 2002). We concluded that IRPDcov conjugates have potential
applications as dual imaging-hyperthermia agents, are more stable in aqueous solution
than IR820, can enhance the effect of hyperthermia in MES-SA and Dx5 cells, improve
cell uptake with respect to free dye, and can provide improved theranostic windows in
vivo.

The conjugation of PEG-diamine with a NIR dye provides a multifunctional delivery
vector whose localization can be monitored with noninvasive techniques and that may
also serve for guided hyperthermia cancer treatments. Future work should focus on
studying the biodistribution of these conjugates in tumor-bearing animals in order to
determine in vivo tumor uptake, as well as on the design and optimization of minimally
invasive in vivo methods for combined imaging and hyperthermia, possibly through fiber
optic technology. Additionally, there may be opportunities for active targeting of these
conjugates. Terminal functional groups in PEG may be conjugated via amide bonding or
bisulfide bridges with proteins, peptides, aptamers, and other small moieties for active
targeting (van Vlerken et al., 2007). Functionalization can create specific interactions
with cell surface receptors and result in enhanced uptake at sites of interest, with the
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subsequent potential for customization of cancer therapies. Finally, it may also be
possible to incorporate other therapeutic agents, such as chemotherapy drugs during
nanoconjugate formulation in order to encapsulate them within the nanoplexes. This
would result in a versatile multifunctional agent providing imaging, chemotherapy, and
hyperthermia capabilities. Image-guided therapy using IR820 conjugates shows promise
for clinical translation as it can be coupled with minimally invasive light delivery
techniques such as endoscopic or orthoscopic approaches.

We believe that there are many unexplored possibilities for customizable IR820
conjugates besides the ones discussed in this dissertation which focused on PEGcontaining conjugates. Researchers are actively pursuing the use of IR820 in different
applications, including the use of IR820 as a blood pool contrast agent, the preparation of
conjugates of IR820 with photodynamic therapy agents, and the incorporation of IR820
into multifunctional nanoparticles (Pandey et al., 2008; Prajapati et al., 2009; Thierry et
al., 2009). Our group also continues to explore possible theranostic applications of IR820.
For instance, one of our formulations covalently coupled IR820 with chitosan to form
IR820-chitosan conjugates that also enhanced hyperthermic cell growth inhibition in
MES-SA and Dx5 cells after 808-nm laser exposure, and can be used for in vitro and in
vivo imaging. In a rat model, IR820-chitosan conjugates were eliminated through the
gastrointestinal tract, with potential applications as contrast agents and gene delivery
vehicles passively targeted to the digestive system. These results highlight the possibility
of developing IR820 conjugates for different applications based on the identity of the
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linker or conjugated moiety, thus creating opportunities for customizable theranostic
agents and furthering the vision of personalized medicine.
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